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Colorectal cancer is an important global health problem as the second most common 
cause of cancer deaths worldwide. The ability to risk-stratify patients according to 
predicted outcome is fundamental to patient management and historically the TNM 
staging system has formed the basis for this. As more is becoming understood about the 
role of the host’s immune response on cancer progression and its influence on outcome, 
there is a growing need to evaluate the potential role of circulating inflammatory 
cytokines as prognostic markers in colorectal cancer.  
In chapter Two, the patterns of disease recurrence were evaluated in a cohort of 237 
patients. Recurrences were observed most frequently within two years of surgery and at 
distant sites. The prognostic value of pre-treatment carcinoembryonic antigen (CEA), as 
the most widely used circulating prognostic biomarker, was also evaluated in a subset of 
this cohort. We found it to be predictive of overall and disease free survival, independent 
of TNM stage and through these findings, we established CEA as a benchmark against 
which novel approaches could then be compared. 
Chapter Three comprises a systematic review whereby seven studies were found to 
evaluate the prognostic value of multiple cytokine analysis. A combined cytokine score 
was utilised in four studies although the individual cytokines used and the methods by 
which they were combined varied between studies. Some promise was shown by applying 
a multi-marker approach to circulating cytokines.  
Chapters Four and Five were prospective studies. In Chapter Four, IL-6, IL-8, IL-1β and 
TNFα plasma levels were compared between subjects who were recruited into three 
ii 
 
groups: healthy controls, stage II disease and stage IV disease. Plasma IL-6 and IL-8 were 
found to differ significantly between patients with stage IV disease and those without. 
Furthermore, when a combined IL8-CEA score was developed, the ability to distinguish 
between the three groups was enhanced, compared to any individual marker. In Chapter 
Five, we went on to evaluate the prognostic value of circulating cytokine markers in a 
longitudinal study. A panel of eight cytokines was selected, each with a foundation in 
experimental data linking their actions to colorectal cancer progression. These cytokines 
were measured in a cohort of 73 patients with non-metastatic colorectal cancer, including 
the combination of IL8 and CEA, developed in Chapter Four. Following a median duration 
of 18 months, combined scores composed of IL-8 and IL-10, when combined with CEA, 
were shown to improve marginally upon CEA alone in risk-stratifying the cohort by disease 
free survival. A number of limitations to the study were acknowledged including a 
relatively small sample size and short follow-up duration, preventing the feasibility of a 
multi-variate survival analysis. 
Whilst we found a multi-marker approach, combining circulating inflammatory cytokines 
with CEA, to offer some promise in colorectal cancer prognostication, further study is 
necessary to evaluate the IL10-CEA score in a larger study sample over a five year follow-
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1.1 Colorectal Cancer 
The colon and rectum in health 
Embryology and anatomy 
Together, the colon and rectum form the large intestine, beginning at the ileo-caecal 
junction and ending at the anal canal. Although variable, its length is approximately 1.5m 
in total and the rectum alone approximately 15cm. The recto-sigmoid junction signifies 
the transition between colon and rectum where three longitudinal muscular bands termed 
taenia coli that run along the length of the colon, fuse to invest the rectum as a single 
continuous layer2. 
The right side of the colon – including the caecum, appendix, ascending colon and 
proximal two-thirds of the transverse colon - is derived from the embryonic midgut and its 
blood supply is via the superior mesenteric artery. The left side of the colon is comprised 
of the distal third of transverse, descending and sigmoid colon – in addition to the rectum 
and is derived from the embryonic hindgut and supplied by branches of the inferior 
mesenteric artery. Draining lymphatic vessels and nodes of the colon and rectum follow 
their arterial supply (Figure 1)2, 3. 
The ascending and descending colon are retroperitoneal structures, whilst the transverse 
and sigmoid colon are typically mobile on a mesentery. The upper rectum is covered by 
peritoneum anteriorly and laterally and anteriorly alone in the mid-rectum. Here, the 
anterior peritoneal reflection lies roughly 7.5cm from the anal verge in men forming the 
recto-vesical fold, and 5.5cm in women as the recto-uterine pouch, or Pouch of Douglas. 
The mesorectum is the perirectal areolar connective tissue which surrounds the rectum 
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beneath the peritoneal reflection down to the levator ani and is enveloped by the 
mesorectal fascia. The mesorectum is traversed by terminal branches of the inferior 
mesenteric artery and contains the draining perirectal lymphatics and lymph nodes of the 
rectum4.  
Four tiers of draining lymph nodes of the colon and rectum have been described: epicolic, 
paracolic, intermediate and principal nodes, which are situated alongside the bowel, 
around the marginal blood vessels, along the main branches of the superior and inferior 
mesenteric artery and at the origin of the mesenteric arteries, respectively 5.  
 
Figure 1. Lymphatic drainage of colon and upper rectum. Image reproduced with permission from 




Venous drainage of the colon and upper rectum is via the superior and inferior mesenteric 
veins which join to form the hepatic portal vein that subsequently enters the liver, 
branching to supply a central terminal venule to individual hepatic lobules. In contrast to 
this, venous drainage of the middle and lower rectum is into the systemic venous 
circulation, via the internal iliac and pudendal veins 2 (Figure 2). 
 
Figure 2. Venous drainage from colon and rectum. Reproduced with the publishers permission. 3 
 
Function, Histology and Physiology 
The main functions of the colon are to reabsorb water and electrolytes within chyme from 
the small intestine. Absorption occurs across enterocytes, which form the most abundant 
cell type in colorectal mucosal epithelium6. Also within the mucosal epithelium are mucin-
containing goblet cells whose secretions line the colon with a moderately bicarbonate-rich 
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mucous; this allows easy passage of faecal material by lubrication and protects the 
mucosal lining from abrasion and acidic by-products of fermentation by commensal 
bacteria 7. Occasional enteroendocrine cells are found within the colonic and rectal 
epithelium and function mainly in feedback mechanisms with the proximal alimentary 
tract to either promote or inhibit motility and secretion8.  
Whilst absorption and fermentation does occur in the left side of the colon and the 
rectum, their function is more concerned with the storage of faeces until expulsion, the 
rectum being an expansive reservoir that is usually empty7.   
The gut flora of the large intestine is formed by several thousands of microbial species and 
various beneficial actions have been acknowledged in the scientific literature9. These 
include, the provision of nutrients via metabolism of indigestible compounds, the 
prevention of colonisation by pathogens, and the production of vitamin K as a metabolic 
by-product10.  
Epidemiology 
In 2012, the GLOBOCAN series of the International Agency for Research on Cancer 
published incidence and mortality data compiled on 184 countries worldwide from 
population-based cancer registries11. In this report, colorectal cancer was found to be the 
third most common cancer behind lung and breast in both sexes combined, third behind 
lung and prostate in men and second behind only breast in women. It had the fourth 
highest mortality rate after lung, stomach and liver11.  
A key finding of the report was the high variability in incidence in Colorectal cancer (CRC), 
ten-fold, between regions of the world and New Zealand was identified as a country with 
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the highest incidence rate observed11. In the year 2015, 3158 new diagnoses of CRC were 
made in New Zealand, with an age-standardised rate of 42.3 per 100 000 population 12, 13.  
The National Cancer Institute of the USA’s Surveillance, Epidemiology, and End Results 
(SEER) program provides incidence and survival trends which have demonstrated a 22% 
increase in incidence of colorectal cancer among adults aged below 50 years between 
1992 and 2013 14. A rising incidence of rectal cancer in younger patients has also been 
observed from Cancer Registry data within New Zealand although the cause of this trend 
is uncertain15. 
The sub-site distribution of cancers are approximately as follows, 40% in the proximal 
colon, 25-30% in the distal colon and 30-35% in the rectum14, 16. A relative increasing 
incidence of right-sided colon cancers and decreasing incidence of left-sided colon 
cancers, termed ‘left-to-right shift’ has been reported in analyses of temporal trends in 
National Cancer Registries both Internationally and within New Zealand16.  
Risk Factors 
A number of hereditary and environmental factors have been linked to an increased 




Table 1. Risk factors for the development of colorectal cancer. Adapted from Haggar et al17 
 
 
Figure 3. Opened colon specimen from a patient with familial adenomatous polyposis. Image 




Physical inactivity and Obesity 
Smoking 







Personal history of adenomatous polyps 
Personal history of colorectal cancer 
Inflammatory Bowel Disease 
Family History of colorectal cancer in first-degree 
relative or second-degree relatives diagnosed under 
50yr 
Familial adenomatous polyposis (FAP) (Figure 3) 
Lynch Syndrome / Hereditary nonpolyposis 
colorectal cancer (HNPCC) 
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Carcinogenesis and Progression 
Carcinogenesis 
Carcinogenesis is a multistep process resulting in the accumulation of genetic mutations 
that may occur spontaneously, as a result of damage, or be inherited; the consequence 
being dysregulated clonal expansion19. The mutations are primarily of proto-oncogenes 
and tumour suppressor genes, resulting in self-sufficient cellular growth and insensitivity 
to growth inhibition, respectively. Oncogene k-RAS activation is considered an early event 
in 40% of colorectal cancers 20, 21. The tumour suppressor gene, p53, functions to prevent 
cell proliferation in the presence of DNA damage, stimulating DNA repair and apoptosis 
and is mutated in up to 70% of colorectal cancers 22, 23. Another tumour suppressor gene, 
Adenomatous Polyposis Coli (APC), underlies 40-80% of sporadic CRCs in addition to 
causing familial adenomatous polyposis (FAP) if affected by germline mutation 21, 24, 25.  
The baseline rate of genetic mutations is considered much too low to result in invasive 
adenocarcinoma and three distinct molecular pathways of genomic instability have been 
described that lead to colorectal cancer26. The first and most common is chromosomal 
instability (CIN). Here, a chromosomal region or entire chromosome is gained or lost and 
this is seen in 70% of CRCs 27. The second pathway is microsatellite instability (MSI), which 
accounts for approximately 15% of sporadic CRC28, 29. It is also the hallmark of hereditary 
non polyposis coli (HNPCC)26, 30. Deficient mismatch repair proteins result in an increased 
frequency of mutations26. MSI is associated with right-sided cancers, mucinous cell type 
and the presence of infiltrating lymphocytes26 and generally carries with it a more 
favourable prognosis31. Thirdly, the CpG island methylation pathway (CIMP) results from 
widespread epigenetic hypermethylation of CpG islands30. This may lead to genetic 
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silencing including of MMR gene promotors and result in MSI demonstrating that the 
three pathways may overlap in CRC30.   
Adenoma-Carcinoma Sequence 
Evidence of a sequence of progression from adenoma to carcinoma, a widely accepted 
model, comes from epidemiological, histopathological and genetic data32. In terms of 
epidemiology, countries with high prevalence of colorectal cancer are also found to have 
high prevalence of adenomatous polyps, both increasing with advancing age and with a 
peak prevalence for adenomas that precedes cancer by roughly five years33, 34. 
Histologically, adenomata have been found to contain foci of invasive cancer in 0.2-8.3% 
of cases, providing evidence of malignant cells arising out of precursor adenoma lesions35, 
36.  
 
Figure 4. Adenoma-carcinoma progression with common genetic mutations. Reproduced with the 
publishers permission. 18 
An example of genetic evidence of the adenoma-carcinoma sequence are studies showing 
p53 mutations to occur within adenomas, invasive foci within adenomas and colorectal 
cancer, with increasing frequency, from 25% to 50% to 75% respectively37 (Figure 4). 
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Serrated polyp-carcinoma sequence 
A distinct pathway, termed the serrated polyp-carcinoma sequence is thought to underlie 
7.5-10% of sporadic CRC. The cancers arise from serrated polyps which include 
hyperplastic polyps, sessile serrated adenomas and traditional serrated adenomas38. 
Adenocarcinoma arising from serrated adenomas are more common in females and tend 
to be right-sided colon cancers 39.  
Diagnosis and investigation 
Clinical Presentation 
A patient with colorectal cancer may come to medical attention through any of the 
following means: i) symptoms, ii) anaemia, iii) screening or surveillance investigation, or 
iv) incidental finding40.  
Symptoms 
Presenting symptoms include change in bowel habit, abdominal pain, rectal bleeding and 
symptoms of anaemia i.e. fatigue, lethargy and shortness of breath41. Blood loss per 
rectum is likely to be more overt the more distal the tumour producing blood that is 
brighter and less mixed with stool than bleeding from more proximal colonic cancers42. 
Bleeding from right sided cancers may be entirely occult and detectable only through 
faecal occult blood testing or the detection of iron deficiency anaemia43. Additionally, 
caecal and ascending colon cancers have been associated with greater daily blood loss 
than cancers elsewhere in the colon or rectum44. Tenesmus, the sudden severe urge to 
defaecate in the absence of stool, and mucosy rectal discharge are symptoms seen more 
specifically with rectal cancer41.  
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Patients presenting with advanced, metastatic disease may present with pain over the 
affected organ (e.g. right upper quadrant pain as a result of liver capsular pain, or 
vertebral bone pain), jaundice may be the presenting symptom of a patient with liver 
mestastases resulting in biliary obstruction45.  
Emergency Presentation 
Approximately 20% of patients with colorectal cancer present as an emergency, with 
intestinal obstruction, perforation or haemorrhage46. Data from 82 000 patients collected 
through the National Bowel Cancer Audit in the United Kingdom, identified age below 50 
or above 80 years, non-white ethnicity, high level of deprivation and particularly the 
presence of dementia as risk factors for emergency presentation47.  
Screening & Investigation 
Screening 
National screening programs are implemented with the goals of earlier detection of pre-
existing colorectal cancer and reducing the incidence of new colorectal cancer through the 
removal of precursor polyps. Clear evidence demonstrates an improvement in survival in 
patients aged between 50 and 75 years through the use of screening with faecal occult 
blood testing (FOBT) and flexible sigmoidoscopy 48-50. The benefit is greatest with regular 
and frequent testing40, 51. Likewise, prevention of colorectal cancer through endoscopic 
polypectomy is also well-documented48.  
The United States Preventive Services Task Force recommends that people aged 50 years 
undergo screening for colorectal cancer40, 52. Data published in 2012 showed that 57.8% of 
patients underwent screening investigation52, 53. The following factors were associated 
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with being more likely to undertake screening: private health insurance, high income, 
college graduates, over 60 years old52. 
In New Zealand, the roll out of a national screening program began in July 2017 and is an 
invitation-based programme offering Faecal Occult Blood Testing (FOBT), with or without 
endoscopy, to those aged between 60 and 74 years old54.  
Investigation  
The investigation of choice for suspected colorectal cancer is colonoscopy55. In addition to 
direct visualisation, this approach also allows polypectomy or biopsy, securing histological 
confirmation. A tattoo is often placed a few centimetres distal to the lesion to aid in 
surgical resection, particularly where the tumour is impalpable. These benefits are not 
conferred in cases where Computed Tomography (CT) colonography is undertaken 
although a meta-analysis of detection rates of colonoscopy and CT colonography 
demonstrated similar sensitivities between the two approaches: 96.1% (95% CI, 93.8-97.7) 
for CT colonography and 94.7% (95% CI, 90.4-97.2) for colonoscopy 55.  
In cases where a complete pre-operative colonoscopy is precluded by an obstructing 
cancer, it is recommended that one is performed as soon after surgery as possible to 
detect potential synchronous cancers. A synchronous CRC is defined as a distinct lesion 
from the primary, diagnosed within six months of the initial cancer and is separated by 
normal bowel. A large population-based study in the Netherlands reported the incidence 
of synchronous CRC in 3.9% of all newly diagnosed CRCs56. Pre-operative identification of 
such lesions may influence the extent of colorectal resection. 
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The presence and extent of metastatic spread is evaluated by CT with intravenous and oral 
contrast, which also allows assessment of local invasion and involvement of adjacent 
structures. It should be noted that the sensitivity of CT to detect peritoneal nodules, nodal 
involvement and transmural mural invasion is limited 57.  
Whilst CT of the chest, abdomen and pelvis is widely recommended to pre-operatively 
stage rectal cancer, CT of the chest is more controversial in colon cancer, where lung 
metastasis is relatively infrequent 58. Some guidelines recommend pre-operative chest X 
ray and CT chest only for suspicious lesions on X ray 59.  
The main aims of loco-regional staging of rectal cancer is to assess the depth of tumour 
invasion, the presence and number of metastatic regional lymph nodes, the 
circumferential resection margin (CRM) and anal sphincter complex involvement. Two 
acceptable approaches include endoscopic ultrasound and T2 weighted magnetic 
resonance imaging (MRI).  
Endoscopic ultrasound provides accurate assessment of the mucosa and submucosa, and 
has performed well in studies assessing T1 and T2 tumours with a sensitivity of 94% and 
specificity 98%60, 61. However, its accuracy diminished for more locally advanced tumours 
and unlike MRI, endoscopic ultrasound was unable to assess mesorectal fascia 
involvement, an important prognosticator. In contrast, MRI has been shown to have a 
sensitivity of 77% and specificity of 94% for predicting circumferential resection margin 62.   
Suspicious lesions of the liver detected on CT may be further evaluated by liver MRI which 
has a proven benefit particularly for small lesions in the presence of hepatic steatosis, 
achieving an overall sensitivity of up to 97% 63.  
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There is conflicting evidence of a benefit from routine Positron emission tomography – 
computed tomography (PET/CT) in pre-operative staging 64, 65. Whilst FDG PET/CT has 
been shown to have a similar sensitivity to CT in detecting liver metastases of 78-95%66, 67, 
studies have demonstrated a superior sensitivity in the detection of extra-hepatic 
disease68. Due to its poor specificity69, 70 however, the role of FDG PET/CT is generally 
limited to the assessment of extra-hepatic disease in patients being worked-up for radical 
treatment of colorectal liver metastases71.  However, the role for PET/CT in suspected 
recurrence is more convincing, particularly in preventing unnecessary laparotomy 72.  
TNM Staging System 
In 1932, Cuthbert Dukes, a London pathologist, published his classification of rectal cancer 
which became one of the earliest colorectal cancer staging systems to be adopted73. In it, 
Dukes’ stage A indicates invasion into the bowel wall and Dukes B invasion through it. 
Dukes C indicates lymph node involvement. The Dukes classification was later modified by 
Gabriel et al in 1935 to subdivide Dukes C into C1 and C2 depending on whether regional 
lymph nodes only or apical lymph nodes were involved, respectively74.  It was not until 
1968 when the Dukes classification was further modified to include Stage D, representing 
distant metastasis 75.  
Michigan researchers Astler and Coller published their own modifications to the original 
Dukes classification in 1954, which became known as the Astler-Coller classification. Stage 
A were lesions limited to the mucous membrane, B1 were those limited to muscularis 
propria, B2 those extending beyond muscularis propria. Stages C1 and C2 corresponded to 




In current practice, pre-operative staging follows ‘TNM classification’ as laid out by the 
American Joint Committee on Cancer (AJCC) and the Union for International Cancer 
Control (UICC) headquartered in Geneva, Switzerland. ‘T’ refers to the primary tumour 
and advancing T stage relates to increasing depth of invasion so that T3 has breached 
muscularis propria and T4 breaches serosa. The ‘N stage’ refers to regional lymph node 
status with advancing N stage relating to an increasing number of lymph nodes found to 
contain malignant cells. The M stage refers to the presence of distant metastatic spread 
(Table 2).  
The 7th edition of the TNM staging classification was published in the year 2009 and 
applies to diagnoses 2010-2016. The 8th edition staging manual was published in year 2016 





























































Table 3. AJCC Stage group according to AJCC staging manual, 8th edition. 1 
T Stage N Stage M Stage Stage 
Group 
Tis N0 M0 0 
T1-2 N0 M0 I 
T3 N0 M0 IIA 
T4a N0 M0 IIB 
T4b N0 M0 IIC 
T1-2 N1/N1c M0 IIIA 
T1 N2a M0 IIIA 
T3-T4a N1/N1c M0 IIIB 
T2-3 N2a M0 IIIB 
T1-2 N2b M0 IIIB 
T4a N2a M0 IIIC 
T3-4a N2b M0 IIIC 
T4b N1-2 M0 IIIC 
Any T Any N M1a IVA 
Any T Any N M1b IVB 
Any T Any N M1c IVC 
 
The eighth edition remains similar to the seventh with two main changes. Firstly, stage 
M1c was included which denotes the presence of peritoneal metastasis. Its inclusion as a 
separate stage to M1b came as a result of studies showing peritoneal involvement to carry 
significantly worse prognosis77, 78 (Table 3). The second change relates to the presence of 
micrometastases (MM) within regional lymph nodes. Defined as clusters of 10 to 20 
tumours cells or clumps of tumour on cut section that measure ≥0.2mm in diameter, MMs 
found within lymph nodes are considered positive according to the eight edition 1. 
Previous editions drew no distinction between the presence of isolated tumour cells (ITCs) 
and MM leading to conflicting results and confusion79, 80. More recently, a meta-analysis 
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and pooled analysis of five studies has found the presence of lymph node 
micrometastases to predict a significantly higher likelihood of disease recurrence in stage I 
and II colorectal cancer (OR 4.94, 95% CI 1.69-14.46) compared to those with isolated 
tumour cells 81.  Patients with ITCs did not have an increased risk of recurrence to those 
without (OR 1.00, 95% CI 0.53-1.88)81.  
Surgery 
Operations 
Surgical resection of the primary tumour with clear margins and regional lymph nodes 
forms the cornerstone for cure for loco-regional disease (Figure 5). Which operation is 
performed relies largely on the location of the tumour and Table 4 summarises potentially 




Table 4. Choice of curative operation, based on primary tumour location. 
Location of tumour Operation  
Appendix Right hemicolectomy 
Caecum Right hemicolectomy 
Ascending colon Right hemicolectomy 
Hepatic flexure Right hemicolectomy 
Proximal transverse colon Right or Extended right hemicolectomy 
Distal transverse colon Extended right hemicolectomy 
Splenic flexure Left hemicolectomy or extended right 
hemicolectomy Descending colon Left hemicolectomy 
Sigmoid colon Sigmoid colectomy / high anterior resection* 
Recto-sigmoid junction High anterior resection* 
Upper rectum Low anterior resection* 
Mid-rectum Low anterior resection* 
Lower rectum >2cm from anal 
verge 
Ultra low anterior resection* 
Lower rectum <2cm from anal 
verge 
Abdominal Perineal Resection 
Multiple sites Subtotal colectomy or proctocolectomy 
 
*or Hartmann's procedure (end colostomy) 





Figure 5. Intra-operative photograph, right hemicolectomy. Following the resection of the right 
colon, the divided ends of the terminal ileum (white arrow) and transverse colon (yellow arrow) 
are joined together using a linear stapling device. Image reproduced with the publishers 
permission. 82 
Total Mesorectal Excision 
The surgical approach of resecting rectal cancers en bloc with the surrounding 
mesorectum was first described by Bill Heald in 1979 and has since revolutionised rectal 
cancer surgery83 (Figure 6). It is based on the principle that the mesorectum contains the 
draining lymphovasculature to the tumour and by employing this approach, Heald 




Figure 6. Intra-operative photograph, anterior resection of the rectum. Total mesorectal excision 
(TME) dissection plane demonstrated anterior to the rectum in a female patient. Image 
reproduced with publishers permission. 85 
Post-operative systemic therapies 
For colon cancer, the benefits of adjuvant chemotherapy have been widely accepted in 
patients with stage III disease where there is a 30% relative risk reduction 86. A 5-FU 
Oxaliplatin-based regime (FOLFOX) is generally recommended 12 and Capecitabine is 
considered an oral alternative with similar survival benefits 87. Amongst the evidence 
supporting routine adjuvant chemotherapy following surgery for stage III disease is a 
systematic review 88 and two RCTs 89, 90 demonstrating an improved disease free survival 
and overall survival.   
By contrast, the evidence in support of routine treatment in stage II colon cancer is much 
scarcer. Four RCTs comparing adjuvant therapy with surgery alone for stage II colon cancer 
have shown no clear survival benefit 87, 89, 91, 92 and cancer societies including the American 
Society of Clinical Oncologists (ASCO), the European Society of Medical Oncology (ESMO), 
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and National Comprehensive Cancer Network (NCCN) do not recommend routine adjuvant 
chemotherapy in these patients. Whilst these bodies have named a number of ‘high-risk’ 
features that may influence the decision of offer treatment the evidence for survival 
benefit in this sub-group is also weak 93: 
• Lymph node yield below 12 
• pT4 tumours 
• Obstruction or perforation 
• Lymphovascular and perineural invasion 
• Histologically high grade tumour 
In rectal cancer, the NCCN recommends routine adjuvant chemotherapy in all patients 
that underwent neoadjuvant chemoradiation 94. This is based on expert consensus 
although a meta-analysis of four European trials was inconclusive in proving a significant 
benefit 95.  
Surveillance and follow up 
The main aim of post-operative surveillance is to detect otherwise clinically silent 
recurrences. In the case of liver or lung oligometastatic disease, this may mean potentially 
curative surgery can be offered 96, with five-year survival rates approaching 40%97, 98. A 
Cochrane review published in 2015 included 53 studies evaluating the ability of 
carcinoembryonic antigen (CEA) to detect post-operative recurrences in colorectal 
recurrence and came to the conclusion that CEA is insufficiently sensitive to be used alone 
99. Most cancer societies recommend both CEA and imaging modalities in post-operative 
surveillance 100-102.  
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The New Zealand Guidelines Group made six recommendations for post-operative 
surveillance in their document ‘management of early colorectal cancer’ 12 published in 
2011, which are: 
• Colon and rectal cancer patients that did not undergo complete colonoscopy before 
surgery should be offered colonoscopy within six months of discharge.  
• Clinical assessment should be undertaken yearly for suggestive symptoms of relapse  
• High-risk patients should have a clinical review every six months to one year for the 
first three years, then yearly for at least five years 
• Low-risk patients should have a colonoscopy every three to five years 
• Clinical assessment for colon cancer patients should include CEA, chest, abdominal and 
pelvic CT scans, or liver ultrasound and colonoscopy  
• Clinical assessments for rectal cancer patients should include CEA, abdominal and 
pelvis CT scans, colonoscopy and proctoscopy or sigmoidoscopy.  
Prognostic Predictors 
Whilst the TNM staging system is recognised as the strongest and most widely established 
prognostic predictor of colorectal cancer, a number of additional clinical-pathological 
factors have been shown to yield prognostic value.  
Emergency presentation. 
Patients presenting with perforation, bleeding or obstruction have been found to exhibit 
poorer five-year survival compared with their counterparts undergoing planned care. In 
their Scottish study, McArdle et al compared the outcomes of 986 patients presenting as 
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an emergency to 2214 of those presenting non-emergently and found the adjusted hazard 
ratio for overall survival to be 1.68 (95% CI, 1.49-1.90, P<0.001) 103.  
Histological grade. 
High histological grade refers to poorly differentiated tumours and is associated with 
worse outcomes. A disadvantage to clinical application of this factor is its subjectivity and 
inter-observer variability104. 
Lymphovascular and Perineural Invasion. 
The prognostic value of lymphovascular105 and perineural invasion106 is well-established in 
colorectal cancer and forms an integral part in the assessment of the malignant polyp 
especially, where the presence of these prognostic markers influence which patients may 
be offered surgery. 
Mucinous adenocarcinoma. 
Mucinous adenocarcinoma is when greater than 50% of a lesion of composed of 
extracellular mucin107. These tumours are associated with right-sided colonic tumours and 
advanced stage at presentation108. A 2012 meta-analysis included 35 studies in a survival 
analysis and found mucinous histology to be an risk factor for recurrence and death109, 110.  
Mismatch Repair (MMR) protein deficiency. 
Deficiency of one or more mismatch repair proteins (MLH1, MSH2, MSH6) is seen in 
patients with Lynch syndrome and 15% of those with sporadic colorectal cancer. This 
results in a high amount of microsatellite instability and is associated with improved five-
year overall and cancer-specific survival111.  
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Lymph Node Yield. 
A lymph node yield of at least twelve is thought to represent an optimal mesenteric 
resection and accurate lymph node stage and is therefore recommended in the AJCC 
staging manual, 8th edition. Diligence and experience of pathology personel is often an 
acknowledged confounder in this parameter 1, 112.  
Lymph Node Ratio. 
The number of positive lymph nodes as a ratio of total lymph node yield has been 
demonstrated to be a powerful prognostic value. Ceelen et al performed a systematic 
review that included 16 studies of patients with stage III colon and rectal cancers. They 
found lymph node ratio not only to be an independent predictor of overall and disease-
free survival but to be superior to lymph node yield 113.  
Isolated Tumour Deposits. 
Tumour deposits are nodules within pericolonic or perirectal tissue away from the leading 
edge of the tumours and with no evidence of residual lymph node. They have been found 
to occur in 2.5% of colon cancers and 3.3% of rectal cancers in the absence of positive 
lymph nodes114. These were previously considered as part of the ‘T’ stage but since the 
AJCC seventh edition now form part of the ‘N’ stage. While studies have found this factor 
to be associated with poorer overall and disease-free survival there are a number of 
interpretation challenges. These include differentiation from discontinuous tumour 
spread, totally replaced lymph node and venous invasion112.   
Circumferential Resection Margin and Tumour Regression Score in Rectal Cancer. 
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Prognostic factors that are unique to rectal cancer include the circumferential resection 
margin, and tumour regression score following neo-adjuvant treatment. A distance of 
1mm or less between the tumour and circumferential resection margin has been shown 
consistently to predict a higher rate of local and distant recurrence1, 115. The status of the 
circumferential resection margin largely, but not exclusively, determines the extent of 
residual tumour in local-regional disease. As defined in the AJCC staging manual R0 
denotes no residual tumour, R1, microscopic residual tumour and R2 macroscopic residual 
tumour116.  
BRAF. 
The BRAF V600E mutation is present in nearly 10% of CRCs. An association has been 
observed between BRAF mutation and female sex, high grade, advanced age and MSI-H 
tumours. The BRAF V600E mutation confers a survival disadvantage among patients with 
microsatellite stable (MSS) disease. Contrastingly, a survival advantage has been observed 
among patients with MSI-H disease 117. 
KRAS. 
Mutations in the Kirsten RAS proto-oncogene (KRAS) have been observed in 30-40% of 
CRCs. The presence of KRAS mutation has been shown to predict response to anti-GFR 
therapy in metastatic disease 118.  
12-gene Recurrence Score assay. 
The Oncotype DX Colon Recurrence Score assay utilises reverse transcription –polymerase 
chain reaction on primary colon tumour tissue. The score was initially developed and 
validated in stage II colon cancer but has since been validated in stage II/III disease treated 
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with adjuvant chemotherapy119. The SUNRISE study in Japan found the Oncotype DX Colon 
Recurrence Score assay to independently predict recurrence in stage II/III colon cancer 
patients who were treated with surgery alone120.  
Serum Carcinoembryonic Antigen. 
The prognostic value of preoperative CEA has been observed in clinical studies as early as 
the 1970’s 121. In 1984, Wolmark et al published the pooled results from two National 
Surgical Adjuvant Breast and Bowel Project (NSABP) trials, based in the USA. They 
reported the preoperative CEA to be associated with disease recurrence in patients with 
Dukes B and C disease 122. A number of other early studies have also demonstrated an 
observed association between raised preoperative CEA and recurrence in colorectal 
disease although many were limited by small study samples 121, 123, 124.  
In the College of American Pathologists Consensus Statement 1999,   preoperative CEA 
was stratified as a ‘Category I’ prognostic factor in colorectal carcinoma by a 
multidisciplinary panel including Oncologists, Pathologists and Statisticians125. This 
indicates the strength of evidence in the available literature at the time. Whilst the 
incorporation of preoperative CEA into the TNM staging system was suggested as the ‘C’ 
stage, it was not adopted in subsequent AJCC staging manuals.  A major reason for this 
was disagreement over the optimum cut off value 126. Contemporary studies have since 
set out to re-evaluate the prognostic value of preoperative CEA in the context of modern 
chemotherapy, although a single cut-off value remains to be universally validated and 
agreed upon. This point is exemplified by the USA-based study of Thirunavukarasu et al 
who analysed data from the National Cancer Institute’s SEER database of 16,619 patients 
with colonic cancer127. They found the ‘C stage’ to significantly effect 5-year survival when 
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incorporated into the TNM staging system. However, a raised CEA was not determined by 
a pre-defined value but by what the reporting physician identified as elevated 128.  
Konishi et al’s 2018 retrospective study examined the prognostic value of pre- as well as 
post-operative CEA in 1027 patients with stage I-III colon cancer undergoing curative 
resection129. Patients with a raised pre-operative CEA that normalised after surgery were 
found to have a similar prognosis to patients with a normal pre-operative CEA. Although 
these results cast doubt on the future utility of pre-operative CEA, a number of questions 
about the prognostic role of post-operative CEA remain unanswered. These include, the 
optimal timing of post-operative measurement in relation to adjuvant therapy and the 
confounding effect of a complicated post-operative course. Further studies are required to 
compare the prognostic value of preoperative CEA in patients with raised and normal 
post-operative CEA in order to address these questions.  
In routine clinical practice around the world, a pre-operative CEA is often not measured. 
Therefore, retrospective analysis is often hampered by a large degree of missing data. This 
is demonstrated in the study of Becerra and colleagues who included 137,381 patients 
with stage I-III colon cancer from the National Cancer Database 130 where pre-operative 
CEA values were available in only 50.6% of the cohort.  
Studies such as that of Sasaki et al demonstrate the prognostic value of pre-operative CEA 
in stage IV colorectal cancer patients undergoing surgery with curative intent. Their study 
484 patients undergoing surgery for colorectal liver metastases were included and found 
an optimum cut off of 70 ng/mL for recurrence and 50ng/mL for survival131. Similarly, pre-




Risk Assessment Models 
There is a shift toward delivering personalised treatment whereby the available data be it 
clinical, radiological, histopathological, molecular or genetic is evaluated to accurately risk 
stratify patients and tailor treatment accordingly. A number of multi-variable risk 
assessment models have been developed to predict prognosis in colorectal cancer and 
twenty-nine such models were identified in a systematic review by the AJCC Precision 
Medicine Core (PMC)1.  Following the application of stringent inclusion and exclusion 
criteria, three of these risk assessment tools were endorsed by the AJCC in their 8th edition 
staging manual. One tool is for use in stage III colon cancer 133, one for predicting survival 
following curative colectomy 134 and a third for predicting outcome in locally advanced 
rectal cancer 135.  
Renfro et al’s 2014 prognostic tool was developed using data from 15 936 stage III patients 
accrued through 12 randomised clinical trials contained in the Adjuvant Colon Cancer End 
Points (ACCENT) database.  The tool uses the following variables: age, sex, race, BMI, 
performance status, T stage, lymph node ratio, grade, chemotherapy agent and tumour 
location.  External validation studies have shown the model to perform well in predicting 
overall survival although the predicted 3-year time to recurrence (TTR) of 80.3% in their 
external validation study fell outside the 95% confidence interval of the observed TTR, 
which was 74.8-78.7% 133.  
Weiser et al’s 2011 model is based on data from 128, 853 primary colon cancer patients 
from the SEER database. The factors included in the model are age, sex, T stage, grade, 
total lymph nodes and number of positive lymph nodes.  In their study, Weiser et al found 
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their risk assessment model to  predict five-year survival with 72% sensitivity and 64% 
specificity134.  
Valentini et al’s 2011 pooled data from five European clinical trials to include 2795 
patients with locally advanced rectal cancer. Multivariate nomograms were developed to 
predict 5-year local recurrence, distant metastases and overall survival. The variables 
included in the risk assessment model for distant metastases, for example, are N stage, T 
stage, surgical procedure and administration of adjuvant chemotherapy135.  
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1.2 Inflammation and Colorectal Cancer  
Population-based evidence for a link between inflammation and 
colorectal cancer 
It has been estimated that 15-20% of the global cancer burden is attributable to, or 
associated with, underlying infection and/or inflammation 136, 137. Examples of this are 
widespread and include: hepatitis and hepatocellular carcinoma 138; human papilloma 
virus and anal and cervical carcinoma139, 140; chronic pancreatitis and pancreatic 
adenocarcinoma141; chronic prostatitis and prostate carcinoma 142; endometriosis and 
endometrial adenocarcinoma 143; thyroiditis and papillary thyroid cancer 144, 145. Patients 
with inflammatory bowel disease (IBD) have an increased risk of developing colorectal 
cancer 146, 147 and the observations that cancer risk is associated with the duration 148 and 
severity149 of disease suggest a causal relationship. Some have suggested a shared genetic 
predisposition to underlie both conditions although a Swedish study of over 30,000 
patients with inflammatory bowel disease found that the risk of colorectal cancer in their 
first-degree relatives was not significantly increased 150.  
Further evidence of a link between inflammation and colorectal cancer comes from 
population studies that have shown a reduced incidence of colorectal cancer 151 amongst 
patients taking regular non-steroidal anti-inflammatory drugs (NSAIDs) 152. It should be 
noted that some of these have been based upon secondary analyses and include large 
studies that were designed to evaluate the risks and benefits of NSAIDs in reducing 
cardiovascular risk. Prospective studies have demonstrated a reduction in the risk of 
colorectal cancer in patients taking aspirin or non-aspirin NSAIDs compared to those 
receiving a placebo, although the effect is often not seen until at least ten years of  
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therapy 153-156. The risks associated with long-term NSAID use are currently considered to 
outweigh the benefits of reducing the incidence of colorectal cancer in the general 
population. However, the US preventative services task force (USPSTF) recommend low-
dose aspirin for primary prevention of cardiovascular disease and colorectal cancer in 
patients aged 50-59 years old with a greater than 10% 10-year cardiovascular disease risk 
157. 
Inflammation within the tumour microenvironment  
Immune and stromal cell populations 
In 1863, Rudolf Virchow described an immune cell “lymphoreticular” infiltrate within 
tumours and first proposed this host immune response to play an important role in the 
origin of cancer 158. Subsequently, numerous populations of immune and inflammatory 
cells have been observed and identified within the tumour microenvironment (TME) of 
sporadic, as well as colitis-associated, CRCs, including: tumour associated macrophages 
(TAMs) 159, dendritic cells 160, tumour-associated neutrophils (TANs) 161 and T cell 
lymphocytes 162. Whilst the TME is generally considered supportive of tumour growth and 
progression, some cellular subtypes display predominantly anti-tumour immune activity, 
namely adaptive immune cells including cytotoxic T lymphocytes 163 and their abundance 
within the microenvironment is associated with favourable prognosis162. This illustrates 
the complex interplay between tumour and host and its influence on tumour progression.  
Tumour-associated macrophages (TAMs) 
Macrophages are one of the most abundant inflammatory cell-type within the TME, 
making up to 80% of the tumour mass 158, 164. Tumour and stromal cells secrete chemo-
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attractants such as C-C motif ligand 2 (CCL2), recruiting circulating monocytes into the 
tumour 165, 166. Here, monocytes differentiate into macrophages under the influence of 
macrophage colony stimulating factor (M-CSF), also produced by tumour cells 167. A body 
of experimental evidence now exists in support of there being two main subtypes of 
macrophage within the TME, M1 and M2 with generally opposing functions168. On the one 
hand, M1 macrophages are ‘classically activated’ and have anti-tumour functions, whilst 
M2 TAMs are ‘alternatively activated’ and have functions that are supportive to tumour 
growth and progression 168. The predominant phenotype is largely influenced by the 
profile of cytokines and chemokines within the tumour microenvironment 169 and TAMs 
demonstrate plasticity so are not committed to one phenotype but may alter with the 
changing biochemical landscape 169, 170. For example, granulocyte monocyte colony 
stimulating factor (GM-CSF) and interferon ɣ (IFNγ) have been shown to stimulate 
development of cytotoxic M1 macrophages 171. The location of TAMs is also important as 
studies have shown intra-tumoural TAMs to increase in density with advancing stage and 
worsening prognosis 172 whereas increasing numbers of peri-tumoural TAMs correspond 
with tumours bearing favourable outcome 39. Some have interpreted this as peri-tumoural 
TAMs to be reflective of an initial immune response that is protective to the host and as 
macrophages infiltrate deeper into the tumour they are ‘entrained’ to take on pro-tumour 
characteristics.  
Tumour-associated neutrophils (TANs) 
Chemo-attractants released by tumour cells, including  interleukin 8 (IL-8), G-CSF and GM-
CSF, attract circulating neutrophils into the tumour where there is evidence that, like 
macrophages, there exist two sub-types within the TME 173. N1 neutrophils are primarily 
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cytotoxic toward tumour cells174 and stimulate a local anti-tumour immune response, 
mediated by T helper 1 (TH1) cells, through the release of TNFα, IL-12, GM-CSF and 
vascular endothelial growth factor (VEGF) 174. The N2 phenotype is activated by tumour- 
and macrophage-derived factors particularly Tumour Growth Factor-β (TGFβ), VEGF and 
IL-10 resulting in a supressed adaptive immune response, thus acting in favour of tumour 
growth and progression 175. N2 neutrophils also act directly to promote tumour growth by 
releasing pro-angiogenic factor VEGF-A and tumour growth factors such as TGFβ, 
epidermal growth factor (EGF) and platelet derived growth factor (PDGF) 173, 175. N2 
neutrophils are also thought to possess pro-metastatic properties and an example of this 
is through the release of matrix metalloproteinase 9 (MMP-9), which in turn leads to 
extracellular matrix degradation: a necessary step in tumour invasion and intravasation 176, 
177.   
Dendritic Cells (DCs) 
Dendritic cells (DCs) play an important role in adaptive immunity as antigen presenting 
cells (APCs) 178. In colorectal cancer, DCs are thought to either migrate to lymph nodes 
where they mature, or mature at the tumour edge itself, where they present cancer-
associated antigens in order to activate an adaptive, T cell-driven, immune response 179, 
180. A potential pathway for tumours to evade immune –detection is by inhibiting the 
maturation of DCs. Michielson et al showed that tumour conditioned media from 
colorectal tumour explants inhibited dendritic cell maturation in response to 
lipopolysaccharide exposure and suggested that this was mainly mediated by CXCL and 




Cancer Associated Fibroblasts (CAFs) 
Fibroblasts form the main cellular component of the tumour stroma and are recruited into 
the TME where they may differentiate into cancer-associated fibroblasts (CAFs) under the 
influence of cytokines including TGFβ, PDGF, and IL-6 182. Unlike for TAMs, TANs and DCs, 
where evidence exists for both tumour-promoting and tumour-suppressing actions, 
studies on CAFs have demonstrated predominantly tumour-promoting effects 182. These 
can be through stimulating tumour cell proliferation and survival through release of 
growth factors including hepatocyte growth factor (HGF), PDGF, fibroblast growth factor 1 
(FGF-1) 183; angiogenesis through VEGF release, and invasion and metastasis through TGFβ 
and MMP-9 release 184.  
Cytotoxic T Cell Lymphocytes (CTLs) 
An increased density of T cell lymphocytes within the TME indicates the presence of a 
strong adaptive immune response and has been shown to be an indicator of favourable 
outcome 185. The ‘immunoscore’, developed by Galon et al, is a validated prognostic score 
based on the density of CD3+ T cells, CD8+ cytotoxic T cells and CD45RO+ memory T cells 
within the central tumour and/or invasive margin 162 and some studies have shown 
immunoscore to outperform traditional TNM staging in predicting outcome in colorectal 
cancer 186. This shows the important influence that host immune response has on 
prognosis.  
T Helper Cells 
Whilst the role of CD8+ cytotoxic T cells in cancer is generally restricted to tumour cell 
clearance, CD4+ T helper cells have much more diverse functions 187. Evidence supports 
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the presence of two main sub-types of T helper cells each with opposing actions within the 
TME 188. Polarisation toward TH1 or TH2 differentiation depends largely on the profile of 
cytokine molecules within the microenvironment 188. Whilst other T helper sub-sets found 
within the TME such as TH17 and Treg cells exhibit plasticity and have mainly regulatory 
actions, TH1 and TH2 cells commit to one lineage or the other once differentiation has 
occurred and together, they represent a polarity that may profoundly impact tumour 
growth and progression 188, 189.  
Polarisation of T helper cells may be toward a predominantly TH1- or TH2-response. Each 
type of response is associated with a distinct profile of cytokines and cellular subtypes that 
effect tumour growth and progression in different ways (Table 5). 
 
Table 5. The immune response to cancer within the tumour microenvironment.  
T Helper Cell 
Response 




IFNɣ, IL-2, IL-12 
Stimulates an anti-tumour immune response through 
activation adaptive immune cells. These include, 
cytotoxic CD8+ T cells, M1 cytotoxic macrophages, N1 




IL-4, IL-5, IL-10, 
IL-13, TGFβ 
Supresses the adaptive immune response. Stimulates 
M2 and N2 cells to promote tumour growth, 
angiogenesis, ECM degradation and invasion. 
 
TH1 cell differentiation is stimulated by IFNγ and IL-12 and, through the release of 
cytokines including IFNγ, IL-2 and IL-12, exert a direct cytotoxic effect on tumour cells. 
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They also help to rally a CD8+ cytotoxic response with the cumulative effect of hindering 
cancer development 190. In contrast to this, TH2 cells release IL-4, IL-5, IL-10 and IL-13 
which inhibit T cell-mediated cytotoxicity 191 and are considered to contribute to a more 
tumour-permissive, immunosuppressed TME 188.  
In addition to their role in tumour cell clearance, there is evidence that TH1 cells also 
influence cells of the innate immune system to differentiate into anti-tumour phenotypes 
such as M1 macrophages, N1 neutrophils and mature antigen presenting dendritic cells, or 
their corresponding pro-tumour phenotypes in the case of TH2 cells 164, 192. Macrophages 
may differentiate into M1 or M2 and neutrophils into N1 or N2 phenotypic subtypes. Unlike 
macrophages and neutrophils, which exhibit some plasticity between subtypes, TH1 and 





Figure 7. Cells of the tumour microenvironment and their action on tumour growth. DC: Dendritic 
cell, CAF: Cancer-associated fibroblast, CTL: Cytotoxic T Cell Lymphocyte. 
Cytokines within the microenvironment  
A vast number of cytokines are found within the tumour microenvironment and are 
products of tumour and stromal cells as well as those of the innate and adaptive immune 
systems discussed above. Whilst many of the central pro-inflammatory cytokines help to 
foster a primarily tumour-permissive microenvironment, others function to amplify and 
mediate anti-tumour effects. Others still have dual functions and do not sit neatly into a 
pro- or an anti-tumour group. Experimental evidence on some of the specific functions 
and downstream activation pathways are set out below for a selection of the most widely 




Interleukin 1β (IL-1β) 
Interleukin 1β is a potent activator of the pro-inflammatory transcription factor, nuclear 
factor Кβ (NF-KB) and is considered to be one of the main inflammatory cytokines 193. NF-
kB activation can occur in tumour cells, epithelial cells or inflammatory cells and its 
downstream actions include the further expression of cytokines, adhesion molecules and 
angiogenic factors with pro-tumour effects 194. Saccani et al demonstrated that while it is 
usually under tight control by its inhibitor (IkB), NF-kB may become constitutively active 
under the influence of cytokines such as IL-1β and this is found to be the case in many 
cancers 195.  
Wang et al demonstrated a pro-tumourigenic role of interleukin 1β by using recombinant 
IL-1RA to block its actions in an in vivo mouse model of colitis-associated cancer 196. This 
resulted in reduced inflammatory cell infiltration and tumour development 196. Other 
studies have shown IL-1β to directly promote tumour cell proliferation and this is thought 
to be through activation of the Wnt-β catenin pathway 197. 
Tumour Necrosis Factor α (TNFα) 
Pro-inflammatory cytokine TNFα has been widely studied in the context of cancer-
associated inflammation. Like IL-1β, it produces many of its carcinogenic and pro-tumour 
actions through activation of the oncogenic transcription factor NF-kB (Figure 8) 194, 198. 
Luo et al demonstrated this in their mouse model of colon adenocarcinoma, where lung 
metastasis growth was prevented by the inhibition of TNFα-mediated NF-kB activation 199. 




Figure 8. Actions of NF-KB (Nuclear factor KB) in tumour microenvironment.  
Interleukin 8 / CXCL8 (IL-8) 
IL-8 expression is frequently increased within CRC tumour tissue compared to healthy 
adjacent intestinal tissue in humans 202. In inflamed tissues, IL-8 release is predominantly 
from myeloid cells after transcription is up-regulated by NF-kB 203, which in turn is induced 
rapidly by TNFα and IL-1β, as discussed above 204.  
IL-8 is a potent chemo-attractant of granulocytes and, particularly, neutrophils to sites of 
inflammation 205. CRC cell line studies have shown that IL-8 promotes tumour growth and 
angiogenesis by activation of Akt and mitogen-activated protein kinase (MAPK) signalling 
pathways 206, 207. Martin et al described the upregulation of VEGF by endothelial cells in 
response to IL8 via NF-kB, independent of hypoxia-inducible factor 1α (HIF-1α) 208. This 
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study implicates IL-8 in a pro-angiogenic pathway that may occur in the absence of 
hypoxia.  
Finally, IL-8 is also thought to contribute toward invasion and metastasis through 
epithelial-mesenchymal transition (EMT) and the expression of matrix metalloproteinases 
in endothelial cells 209, 210.  
Interleukin 6 (IL-6) 
Interleukin 6 is one of the most extensively studied cytokines in CRC as it plays a central 
role as a prototypic pro-inflammatory cytokine 211. Historically, macrophages have been 
thought to be the main source of IL-6 in the TME but CAFs are also thought to be a major 
contributor 212, 213. IL-6, along with its family members IL-11 and IL-27, play a central role in 
cancer progression as activators of oncogenic transcription factor pathway Janus kinase 
(JAK)- signal transducer and activator of transcription 3 (STAT3) 193, 214. The JAK/STAT3 
pathway may also be activated by HGF and EGF 215.  
Downstream actions of the IL-6/JAK/STAT3 pathway include tumour cell survival, 
proliferation, migration and angiogenesis 216. The latter is thought to be through increased 
VEGF-A transcription in response to HIF-1 217.  
In addition to this, there is also evidence of an immunomodulatory role of IL-6. Tsukamoto 
et al demonstrated this in IL-6 deficient mice, where IL-6 produced by myeloid-derived 




Tumour growth factor β (TGFβ) 
The effects of TGFβ on tumour growth within the TME have been described as dualistic to 
the point of being named the molecular Jekyll and Hyde of cancer 219. Studies have 
demonstrated the context-specific nature of TGFβ’s effects as initially tumour-suppressive 
in epithelial cells and then tumour-promoting in the later stages of cancer development 
219. The SMAD proteins one to nine (SMAD1-9) are effector proteins downstream of the 
interaction between members of the TGFβ superfamily and their receptors 220. SMAD4 lies 
at the convergence point of these pathways and is found to be abnormally expressed in 
20-30% of CRCs 221. Experimental studies are hampered by most SMAD4 knockout mice 
dying in utero 220 but Freeman et al reported a ten-fold increase in colonic adenomas in 
heterozygous mice 222. These findings support the tumour suppressor role of TGFβ. 
In contrast, colorectal cancer stem cells treated with TGFβ have been noted to increase 
their invasive and metastatic potential as well as their ability to promote angiogenesis and 
suppress adaptive T cell immune responses 223. In their review, Yao et al describe a large 
body of evidence in support of TGFβ acting as an important regulator of EMT, endowing 
growing cancers with the potential to intravasate and therefore disseminate 224.   
Interferon ɣ (IFNɣ) 
Interferon gamma is produced primarily by T cell lymphocytes and natural killer cells and 
plays an important role in anti-tumour immunity 225, 226. Some of its main 
immunomodulatory effects include the activation of cytotoxic T cells, stimulating major 
histocompatibility- (MHC-)mediated antigen presentation pathways and inducing a TH1 
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helper cell response 227. IFNγ also has a direct inhibitory effect on cancer growth and may 
induce cancer cell apoptosis via Bcl-2 downregulation 228.  
Interleukin 10 (IL-10) 
Interleukin-10 is a potent anti-inflammatory cytokine produced by tumour cells in addition 
to a range of immune cells including M2 macrophages, dendritic cells, B cells and TH2 cells 
229. Its signalling is through JAK/STAT pathways and functions predominantly as an 
immunoregulatory molecule 230. As IL-10 may inhibit both innate and adaptive immune 
processes it has been shown to exert a combination of both anti-tumour and pro-tumour 
downstream effects 202, 231. Pro-tumour effects of IL-10 include inhibition of dendritic cell 
maturation and anti-tumour effects result from inhibition of NF-kB 229. 
Summary 
In addition to tumour cells, the cellular infiltrate within the tumour microenvironment is a 
mix of inflammatory cells of the innate and adaptive immune systems as well as stromal 
cells such as fibroblasts. Some of these cell types display polarisation toward sub-types 
which in turn have primarily pro- or anti-tumour actions and in the case of neutrophils and 
macrophages display a certain plasticity which allows them to ‘change sides’ depending on 
the biochemical landscape. Through the actions of cytokines, these cell-types have the 
ability to influence local processes such as tumour growth, angiogenesis and invasion as 
well as enlist haematopoietic and lympho-reticular cellular resources from the circulation. 
Many of the signalling pathways involved are overlapping, with oncogenic transcription 
factors NF-kB and STAT3 being central players, and cytokines may stimulate their own 
expression through autocrine or paracrine feedback loops. 
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Cancer-related Inflammation: Systemic Processes  
Our understanding of the interaction between inflammation and cancer has been derived 
primarily from pathways acting within the local microenvironment, covered previously. 
Although a relatively young field, there is a growing body of evidence suggesting an 
important role for inflammation on cancer progression at the systemic level (Figure 9)232. 
McMillan et al observed an association between raised pre-treatment C Reactive Protein 
(CRP) and poor prognosis in patients following curative surgery for colorectal cancer 233 
and consequently went on to develop the modified Glasgow Prognostic Score (mGPS) 234. 
The score, which combines CRP with albumin has since been validated in a number of 
cancers alongside colorectal 235 with other scoring systems following suite, similarly based 
on indicators of systemic inflammation. Most notably, this includes the neutrophil-
lymphocyte ratio 236. Despite the challenges in implementing experimental models of 
organism-wide effects of cancer-related inflammation, a number of mechanisms have 
been proposed. 




As discussed previously, tumour-derived chemokines act locally to attract inflammatory 
cells from the surrounding tissue. In addition to this, there is evidence that tumours 
release factors such as G-CSF into the circulation in order to mobilise circulating cells from 
distant reservoirs, particularly the bone marrow and spleen 237, 238. A raised circulating 
neutrophil count is frequently observed in patients with advanced colorectal cancer as 
well as other malignancies 161 and mouse models have supported this relationship to be 
causal, where mice inoculated with tumour develop an acute neutrophilia 173, 239. In 
addition to the number of circulating neutrophils, the morphology has also been found to 
differ between cancer patients and healthy volunteers 240. Low density neutrophils (LDNs) 
have been described, that are scarcely found in healthy cases and found with increasing 
frequency in cancer cases in association with increasing tumour growth 240. The function 
of LDNs are thought to differ from high density neutrophils (HDNs). Granot et als’ series of 
experiments using a mouse model of breast cancer showed G-CSF-stimulated circulating 
neutrophils to possess cytotoxic ability and thus inhibited metastatic seeding 239. In 
contrast to this LDNs inhibited CD8+ cytotoxic T cell proliferation and exhibited reduced 
cytotoxicity toward cancer cells, allowing them to grow and divide 161. Whether LDNs or 
HDNs are mobilised into the circulation is thought to be determined by the specific 
cytokines released by the primary tumour. This hypothesis arose from studies such as that 
by Marini et al who found that G-CSF administration to healthy volunteers led to an 





In addition to the influence circulating neutrophils have on anti-cancer immune 
mechanisms, Regulatory T cells (TReg) play an important role in cancer-induced 
immunomodulation. TReg cells are a subset of CD4+ T cells that are necessary under 
physiological conditions to prevent auto-immunity. They are activated by TGFβ and IL-10 
and inhibit anti-tumour immunity through direct action on CD8+ cytotoxic T cells and by 
preventing dendritic cell maturation 242-244. In their study using hepatocellular carcinoma 
cell lines, Yang et al demonstrated that Treg cells were attracted into the tumour 
microenvironment via a TGFβ-dependent pathway and that this was necessary for 
metastasis to occur in mice 245.  
Endothelial activation  
Endothelial activation has been observed in metastatic colorectal cancer patients, 
indicated by raised serum levels of soluble endothelial cell adhesion molecules, e-selectin 
and vascular cell adhesion molecule 1 (VCAM-1) 246. Endothelial activation is thought to 
promote metastasis by the expression of cell surface adhesion molecules that trap 
circulating tumour cells 247. Additionally, the release of chemokines by activated 
endothelial cells attract host inflammatory and immune cells to create a receptive 
microenvironment 247. Okahara et al’s study on a murine lung-metastasising model of 
melanoma found that inoculation of the mice with TNFα led to endothelial activation and 
increased metastasis formation 248. Together, these findings suggest that endothelial 
activation at distant sites may be a means through which primary tumour-derived 




Thrombocytosis, a raised circulating platelet count, is frequently observed in patients with 
colorectal cancer compared to healthy controls and has been reported to increase in 
metastatic disease 249. The platelet count has also been noted to correlate with circulating 
cytokine levels, particularly interleukin-6 250. Kuznetsov et al’s study on mice carrying 
luminal breast cancer cell xenografts produced platelets that contained pro-angiogenic 
and pro-inflammatory cytokines including TGFβ1, VEGF and IL-6 251. Platelets have been 
implicated in other pro-metastatic pathways through direct contact and interaction with 
circulating tumour cells. This has been demonstrated through inducing the expression of 
IL-8, MMP-9 and VEGF 252, and by inducing endothelial-mesenchymal transition via TGF-β 
and NF-kB signalling 253.  
Pre-metastatic niche formation 
The ’seed and soil’ theory was first proposed in 1889 by Stephen Paget, who examined 
post-mortem data from 735 women with breast cancer and determined metastases to be 
preferentially distributed toward favoured organs 254. Paget went on to hypothesise that 
both tumour cells with metastatic potential (the ‘seed’) and a receptive environment (the 
‘soil’) at predetermined sites, were necessary to form metastatic deposits 255. 
Contemporary evidence has continued to support this theory and points to biochemical 
and cellular changes that occur within distant organs, leading to a supportive 
microenvironment, termed the ‘pre-metastatic niche’ 256. Tumour-derived secreted 
factors as well as immune, inflammatory and stromal cells are thought to contribute to its 
formation 257.  
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In their important study, Kaplan et al demonstrated VEGFR+ bone marrow derived cells 
(BMDCs) ‘homing’ to distant organs prior to the arrival of tumour cells in mice 256.  They 
also found evidence that soluble factors derived from the primary tumour acted on 
fibroblasts at distant sites to upregulate growth factors that then contributed to a 
permissive microenvironment to incoming tumour cells 256. Yamamura et al found 
fibroblasts in the pre-metastatic niche to secrete TGFβ and matrix metalloproteinases, 
which in turn are known to influence tumour growth and progression by acting in a 
paracrine manner 258. Alterations in the local levels of inflammatory cytokines have also 
been reported to include a reduction in interferon gamma and increases in TH2 cytokines 
and MMP-9 in the pre-metastatic lung 259. Rutowski et al described the mobilisation and 
accumulation of MDSCs (myeloid-derived suppressor cells) within the pre-metastatic 
organs of mice, which was found to be driven by IL-6 and IL17 260.   
Neutrophils have been implicated in the formation of a pre-metastatic niche, particularly 
in the lungs. Wu et al carried out experiments on 4TI mammary carcinoma and Lewis lung 
carcinoma models in mice and found that a high neutrophil infiltration was observed in 
pre-metastatic lungs, a process thought to be mediated by G-CSF 261, 262. In addition to this, 
Wculek and Malanchi showed neutrophils to be a main component of tumour growth 
within the pre-metastatic lung in mouse breast cancer models 263. Matrix 
metalloproteinase 9 is also thought to play an important role in inducing pro-tumourigenic 
effects of neutrophils within the pre-metastatic lung 264.  
Studies examining pre-metastatic niche formation using colorectal cancer models are 
relatively sparse. One such study is that by Seubert et al who demonstrated primary 
tumour-derived tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) was necessary for 
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hepatic metastasis of colon cancer cells 265. A study by Wang et al found that CXCL1 
secreted from TAMs within the primary tumour microenvironment recruited MDSCs into 
the pre-metastatic liver in colorectal cancer, and that CXCL1 production was in turn 
stimulated by tumour-derived VEGF 266. These studies suggest that a pre-metastatic niche 
may develop in colorectal cancer and that tumour- and immune cell-derived soluble 
factors influence their formation. Additionally, Shao et al demonstrated tumour-derived 
small extracellular vesicles to specifically target the liver where a pro-inflammatory pre-
metastatic niche was established through IL-6 secretion by Kupffer cells 267. The 
extracellular vesicles were found to be rich in micro RNA (miR-21), a marker that itself has 
been shown to correlate with prognosis 268.  
Circulating Tumour Cells 
Tumour cells that enter the systemic circulation through venous or lymphatic drainage of 
the tumour, known as circulating tumour cells (CTCs), are a necessary precursor to 
haematogenous metastases through seeding of distant organs. Two pathways of 
intravasation of tumour cells have been described, the first being through EMT whereby 
tumour cells de-differentiate before taking on a mesenchymal phenotype with increased 
invasive and migratory ability to enter established blood vessels 269. A second pathway 
that has been described more recently is through passive ‘tumour shedding’ of CTCs into 
neo-vascular structures. This is considered to occur at a much earlier stage in tumour 
progression, with some suggesting it to occur as early as the angiogenic switch, soon after 
a tumour has acquired invasiveness 270. This has led to interest in quantifying CTCs as a 
means of predicting early-stage metastases. Whilst CTCs, particularly when found in 
clusters, have shown some promise in predicting prognosis 271, there are some significant 
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disadvantages. The rarity and heterogeneity of CTCs has made accurate quantification 
technically challenging 272. Furthermore, less than 0.02% of CTCs are thought to result in a 
metastatic mass 270. This is due to inefficiencies of metastatic colonisation which is 
considered to be the rate-limiting step and influenced also by the permissiveness of the 
local microenvironment.  
In their study using the B16F0 melanoma cell line in mice, Li et al showed that circulating 
tumour cells triggered a systemic inflammatory response (indicated by raised serum G-CSF 
and IL-6 levels), resulting in increased pro-metastatic neutrophil infiltration and MMP-9 
expression within the lung. In their model, metastatic colonisation was inhibited by 
administration of anti-inflammatory cytokine, interleukin-37 273. Divella et al 
demonstrated this principle to translate to humans, by reporting circulating inflammatory 
cytokines TGFβ and CXCL1 levels to be significantly associated with the presence of 
clustered CTCs and worse survival in patients with metastatic colon cancer 274.   
Summary 
A number of mechanisms have been proposed linking systemic inflammation to CRC 
growth and progression. Cells within the primary microenvironment may enlist these 
mechanisms to facilitate their own growth or to produce alterations at distant sites that 
aid dissemination. There is also evidence that inflammatory changes occur even before 
the arrival of tumour cells at so-called pre-metastatic niches. Furthermore, interactions 
that occur between tumour-related cells within the circulation also influence the systemic 
immune and inflammatory environment and consequently may have a bearing on primary 
and metastatic progression.   
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1.3 Prognostic studies linking systemic inflammation to outcome in CRC  
Basic science research has led to a growing appreciation of the interaction between the 
tumour and its host275. In parallel to this, clinical studies have set-out to apply this 
principle by evaluating the relationship between systemic inflammation and prognosis. 
This has been driven in part by a need to better prognosticate and subsequently guide 
individualised treatment strategies. The TNM staging system is the current gold standard 
and has been applied in a form that has remained largely unchanged for decades. The 
system is based on a paradigm of linear metastatic progression from local invasion, 
through lymphatic spread, to distant metastasis that has recently been challenged 276. An 
alternative model termed the parallel progression model is now becoming increasingly 
recognised whereby distant metastasis is a potentially early event leading to deposits that 
then develop in parallel to that of the primary tumour 270, 276, 277. Study into systemic 
markers of cancer prognosis has accelerated in response to this proposed mechanism. 
 C Reactive Protein and the Glasgow Prognostic Score 
The Glasgow prognostic score (GPS) has been studied in a number of cancers since it was 
first reported to predict poor prognosis in non-small-cell lung carcinoma by Forrest et al 
seventeen years ago 278. Combining pre-treatment serum levels of CRP and albumin, the 
score is based on the criteria shown in Table 6. Prior to its modified form, GPS originally 
included a score of ‘1’ for an isolated hypoalbuminaemia although this was subsequently 




Table 6. Scoring criteria of modified glasgow prognostic score (mGPS).  
Criteria Score 
C-Reactive protein ≤ 10 mg/L  0 
C-Reactive protein > 10 mg/L and albumin ≥ 35 g/L 1 
C-Reactive protein > 10 mg/L and albumin <35 g/L 2 
 
McMillan et al performed a systematic review of the literature and reported 28 studies 
(n>8000) evaluating the prognostic value of GPS/mGPS in patients with operable cancer 
and found all 28 studies to demonstrate a statistically significant multivariate hazard ratio 
235. The Glasgow group represents a dominant presence in this field, which in itself may 
have introduced bias into the review; eight out of twelve studies limited to patients with 
primary colorectal cancer were performed by their group. A further meta-analysis was 
performed more recently by Liu et al and focussed on the prognostic value of GPS in 
colorectal cancer 279. Including 25 studies (n=5660), they concluded that increased GPS 
was closely associated with overall survival and cancer-specific survival both in primary 
operable and advanced inoperable disease 279. Both systematic reviews highlighted inter-
study heterogeneity and that a large proportion of studies were limited by a retrospective 
design. Whilst both review articles noted an association between GPS and TNM stage, 
they also reported the association of GPS with prognosis to remain present once TNM 




Neutrophil lymphocyte ratio (NLR), Platelet lymphocyte ratio (PLR) & Lymphocyte 
monocyte ratio (LMR) 
A number of indices based on inflammatory markers within the full blood count have been 
shown to yield some prognostic benefit in CRC 280. The most widely studied of these is the 
neutrophil-lymphocyte ratio (NLR), which was initially developed as a marker of sepsis 
severity in critically ill patients 281. Its application to cancer was thought to reflect a 
combination of increased pro-tumour systemic inflammation and a reduced anti-tumour 
adaptive immune response, indicated by neutrophilia and reduced lymphocyte count, 
respectively 282. Although the results of some studies have been equivocal particularly in 
predicting recurrence in rectal cancer 283, 284, overall, NLR is considered a reasonable 
prognostic indicator 236. On one hand, NLR has the advantage of being inexpensive and 
calculated from laboratory tests that are ordered routinely in the pre-operative setting. 
On the other hand, like the evidence for GPS, the majority of studies are also limited by 
their retrospective design.  
Additional indices including the platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte 
ratio (LMR) have since emerged as markers that also reflect inflammatory processes at the 
tumour level and systemically and show an association with outcome 285. Chan et al’s 
recent Australian study included 1623 patients that underwent curative resection 286. 
Although it was a retrospective analysis in which 954 patients were excluded due to 
missing data, its large sample size allowed sub-group analysis to be performed by stage. A 
significantly better overall survival was seen in patients with a high LMR by individual 
stage and, by comparison, the LMR was touted as a superior prognostic marker to the 
more established GPS and NLR 286.  
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A disadvantage shared by each of these indices is that the function of their cellular 
components show some plasticity and may be influenced by interactions with cytokines. 
As discussed previously, neutrophils for example take on a phenotype with predominantly 
pro- or anti-tumour effects depending on the milleu of cytokines they are exposed to. 
Therefore simply quantifying these cells is unlikely to yield optimal prognostic value. 
Likewise, CRP is an acute phase protein produced and released by hepatocytes in response 
to stimulation by pro-inflammatory cytokines, including IL-6 287. Attention therefore has 
turned appropriately upstream to individual circulating cytokines.   
Cytokines and prognosis in CRC 
Interleukin-6 is the most studied cytokine for its prognostic value in colorectal cancer. Two 
meta-analyses have been published on this topic and include a combined total of eleven 
unique studies 288-298. Both reviews concluded that pre-treatment circulating IL-6 levels 
were predictive of 5-year overall survival 299, 300. However, neither review were conclusive 
as to whether IL-6 predicted recurrence. This was cited to be due to a lack of available 
data and heterogeneity between studies 299, 300. Additionally, the sample sizes of the 
studies were small, with only three studies including more than 100 patients 295, 297, 298. 
More recently, a study by Shiga et al evaluated the ability of pre-treatment IL-6 to predict 
recurrence in 207 CRC patients undergoing curative intent resection 301. The study found 
IL-6 to be an independent predictor of recurrence and found this to be the case for TNM 
stage II (n=60) patients in sub-group analysis (p=0.01) 301. As a prospective study that was 
sufficiently powered to include sub-group analysis of recurrence in stage II patients the 
study by Shiga et al was well-designed, although further clinical study is necessary to 
validate these findings.  
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In addition to IL-6, a wide spectrum of cytokines have been shown to correlate with 
prognosis in colorectal cancer. These include pro-inflammatory cytokines (IL-1β 302, TNFα 
303, TGF-β 304), anti-inflammatory cytokines (IL-10 305, IFNɣ 306), chemokines (IL-8 307, CXCL1 
308), pro-angiogenic factors (VEGF 295), proteinases (MMP-9 309) and factors that stimulate 
haematopoietic cell production (M-CSF 310). Overall, the studies are limited by small 
sample sizes and a high degree of inter-study heterogeneity. A systematic review of 
prognostic studies evaluating multiple cytokines is included in Chapter Three of this thesis. 
1.4 Shortfalls of the TNM staging system 
The TNM staging system is currently the best known and most widely implemented 
method of predicting prognosis in CRC. However, prognostic biomarker research in CRC is 
fuelled by growing criticism of the TNM paradigm.  
At its foundation, the TNM staging system remains tied to the archaic Dukes’ 
classification73 which implies a sequential progression from local invasion through regional 
lymph node involvement to distant metastasis. Anatomically, metastasising tumour cells 
may reach the systemic circulation and hence distant organs not only by lymphatic spread 
(via the thoracic duct) but also by haematogenous means311. This gives rise to the 
potential bypassing of the regional lymph nodes 311. Although lymph node involvement 
may be considered a surrogate marker for more advanced disease a growing body of 
evidence challenges this premise by supporting what has been termed the ‘parallel 
invasion model’ 277, 312. Here, metastases arise from tumour cells that disseminate early in 
the development of the primary tumour; distant metastases then progress in parallel to 
the primary tumour277. This model is supported by genetic studies277, 313 such as that by 
Naxerova et al where corresponding samples from the primary tumour, regional lymph 
56 
 
nodes and distant metastases from individual patients were found to be genetically 
distinct276.   
A further flaw of the TNM staging system in colorectal cancer is the heterogeneity of 
outcomes in patients of the same TNM stage 314. For instance, according to analyses from 
the Surveillance, Epidemiology, and End Results (SEER) database, 5-year survival in 
patients with stage II colon cancer range from 87.5-58.4%, depending on T stage315. 
Additionally, 5-year survival rates in patients with stage III ranged from 90.7% to 15.7% 
depending on the T stage and N stage315. Similarly wide ranges were seen amongst stage II 
and III rectal cancer with a large overlap seen between them 315. The SEER database is a 
population-based database that represents 26% of the United States and is maintained by 
quality assurance studies that set a standard of 98% accuracy 316. Whilst this does make it 
a robust resource, results may also be confounded by stage II patients receiving less 
aggressive therapy and comprising a higher proportion of patients with inadequate lymph 
node sampling317. Additionally it is noteworthy that the SEER database collects data on 
survival and not recurrence. However, the so-called “survival paradox” between stage II 
and III colorectal cancer has been further demonstrated in studies that have set out to 
address these issues 318, 319. For example, Kim et al’s study of 5,547 South Korean 
colorectal cancer patients demonstrated a worse overall survival (p=0.012) and disease 
free survival (p=0.001) in patient with IIB/C disease compared to those with IIIA despite an 






The overall aim of this thesis was to investigate the relationship between circulating 
inflammatory cytokine levels and prognosis in patients undergoing treatment of colorectal 
adenocarcinoma with curative intent. In contrast to more established prognostic factors, 
many of which are based on tumour extent and biology, our approach seeks to evaluate 
the host-response and its influence particularly on disease recurrence. This in turn may 
have implications for patient selection for different treatment and follow up strategies, 
whether curative or palliative; aggressive or conservative; intensive or standard 
surveillance. 
The specific aims of this thesis were: 
• To determine the clinical and pathological predictors of disease free survival and 
overall survival in a local population of patients suitable for treatment with curative  at 
our Institution 
• To perform a systematic review of the literature evaluating the prognostic value of 
cytokine analysis in colorectal cancer utilising a multi-marker approach 
• To compare baseline levels of plasma IL-6, IL-1β, TNFα and IL-8 between three groups: 
healthy control, stage II and stage IV CRC and to compare cytokine profiles with C-
reactive protein (CRP) and carcinoembryonic antigen (CEA) 
• To perform a pilot study of baseline plasma IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, IFNϒ and 
TNFα as predictors of disease free survival in patients undergoing treatment of 







2 Chapter Two  
Retrospective Cohort Study of 
Prognostic Predictors following 




Disease recurrence represents a failure of treatment with curative intent. Therefore, 
understanding the timing, location and risk factors of recurrence is essential to guiding 
appropriate treatment. For example, adjuvant chemotherapeutic agents, with their 
inherent risks and side effects, are likely to be of limited value in patients at already low-
risk of recurrence. Furthermore, the incidence of disease recurrence among a patient 
group can be considered a measure of size of the clinical problem. A detailed evaluation of 
the patterns of recurrence may also provide insights into the mechanisms by which they 
occur, in the context of current clinical practice. Additionally, an analysis of the cohort 
characteristics and outcomes at our Institution allow comparison against International 
standards which, in turn, is necessary to establish the validity of this and future studies 
based at our Institution.  
As outlined in Chapter One, a number of clinicopathological factors are considered 
established predictors of prognosis. These include, emergency presentation, TNM stage, 
high histological grade, mucinous cell-type, lymphovascular invasion, peri-neural invasion 
and pre-operative CEA. Furthermore, CEA is a widely available circulating biomarker, 
whose prognostic value in colorectal cancer is supported by a time-tested body of 
literature. Therefore, assessing pre-operative CEA as a prognostic biomarker in a local 
cohort study is an important step toward establishing it as a comparator against which to 





The aims of this chapter are: 
• to determine the characteristics of a local population of patients suitable for 
treatment with curative  at our Institution, including: 
• the proportion of patients presenting in each TNM stage  
• the pattern of disease recurrence in terms of timing and location 
• the clinical and pathological predictors of disease free survival and overall survival 








• Consecutive patients over the age of 18 years undergoing surgery with curative intent 
for newly diagnosed primary adenocarcinoma of the colon or rectum between January 
2010 and December 2012 at our local institution were eligible for this study. 
Exclusion criteria: 
• Patients with a personal history of colorectal malignancy,  
• Patients with stage IV disease at presentation that had residual disease following 
definitive treatment (R1 or R2) 
• Patients in whom post-operative follow-up and surveillance was performed at another 
institution 
• Patients with a complete pathological response to neoadjuvant therapy 
Data collection 
Patients were captured by performing a search of the records of operating theatre cases, 
histopathology specimens and hospital discharges. Data was collected from electronic 
hospital records, which included: operation notes, clinic letters, multi-disciplinary team 
meeting discussions, radiology reports and laboratory and histopathological results. The 
site of primary cancer was taken from the operation note and ‘disease stage’ was assigned 
in accordance with the American Joint Committee on Cancer (AJCC) Seventh edition 5. 
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Where available, pathological staging was taken over clinical staging and those with 
complete pathological response were classified as Stage I. 
Surgery 
Surgery for rectal cancer was typically carried out by three colorectal surgeons and colon 
cancers by general and colorectal surgeons at the hospital. 
Follow Up Protocol  
A standardised protocol for post-operative follow-up and surveillance was used during the 
study period and included three to six monthly surgical outpatient visits and yearly 
computed tomography (CT) scans of the chest, abdomen and pelvis for the initial three 
years. A complete colonoscopy was performed within a year of surgery if one had not 
been performed pre-operatively with a repeat colonoscopy after three years. Yearly 
outpatient appointments were scheduled between years three to five and three monthly 
serum carcinoembryonic antigen (CEA) was checked for all five years.  
Assay 
Serum carcinoembryonic antigen levels were measured at the Wellington Hospital clinical 
laboratory by electrochemiluminescence using the commercially-available Roche Cobas 
6000 analyser and the e601 assay, with a detection limit range of 0.200-1000nG/mL.  
End-points 
The primary endpoint studied was Disease free survival (DFS), defined as the time from 
surgery to recurrence or death 320. Secondarily, Overall survival (OS) was studied and 
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represented the duration from time of surgery to all-cause mortality. Patients that were 
alive and without evidence of disease recurrence on 1st November 2016 were censored. 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics Version 24.0. For continuous 
variables, a distribution with a p-value of greater than 0.05 found on Shapiro-Wilk testing 
was considered normal. Means were expressed with standard deviation for variables 
demonstrating a normal distribution and medians were expressed with interquartile range 
for those not demonstrating a normal distribution. X2 test and Fischer’s exact test were 
used for comparisons of categorical variables and Student t-test and Mann-Whitney U-test 
for continuous parametric and non-parametric variables, respectively.  
A Receiver Operator Characteristics (ROC) curve was used to estimate the optimal cut-off 
value for CEA, using DFS as the endpoint of interest. The optimal cut-off corresponded to 
the point closest to 1.0 sensitivity -0.0 specificity on the ROC curve. The cohort was then 
divided into ‘High CEA’ and ‘Low CEA’ groups using this cut-off point.  
Kaplan-Meier curves were plotted to evaluate DFS and OS and the Mantel Cox log-rank 
test performed to compare groups. Univariate and multi-variate survival analyses were 
performed using Cox proportional hazards model including variables with p<0.1 on 
univariate analysis into a multi-variate model optimised through the backward step-wise 





Ethics and governance 
This study complied with regulations for audit at the host institution and met the New 
Zealand definition of observation research. National ethics committee approval was not 
required for this study. 
2.3 Results – All Patients 
Patient and tumour characteristics 
Two hundred and thirty seven patients were included in the study including 116 males and 
121 females with a median age of 71 years (range 32 to 91 years). Two hundred and nine 
patients (88.2%) were European, 10 (4.2%) of Māori and nine (3.8%) of Pacific Island 
ethnicity. Fifty-nine (24.5%) cancers were rectal, 21 (8.7%) recto-sigmoid and the 
remaining 157 (66.2%) colonic. Thirty-six (15.2%) patients required an emergency 




Table 7. Clinicopathological data of patients undergoing treatment of colorectal cancer with 
curative intent. 
    n=237 (%) 
Age, years (Range) 71   (32 – 91) 
Gender 
  Male 
  Female 
 
116  (48.9) 
121  (51.1) 
Co-Morbidities  
  0 156 (65.8) 
  1 63   (26.6) 
  2+ 18   (7.6) 
Site  
  Rectum 59   (24.5) 
  Colon 178 (75.1) 
Stage  
  I 39   (16.5) 
  II 90   (38.0) 
  III 98   (41.4) 
  IV 10   (4.2) 
Emergency  36   (15.2) 
  Obstruction 26   (11.0) 







The operations performed for primary colorectal cancer were, right hemicolectomy or 
extended right hemicolectomy (n=97); transverse colectomy (n=3); left hemicolectomy 
(n=9); anterior resection (n=81); Hartmann’s procedure (n=15); abdominal perineal 
resection (APR) (n=20); subtotal colectomy (n=11); proctocolectomy (n=2); transanal 
excision (n=1).  
Of the ten patients with stage IV disease at presentation, one had an oophorectomy for an 
ovarian metastasis at the time of initial surgery. The remaining nine had surgery for 
synchronous metastases following an interval (range 98-215 days) after the initial surgery.  
Six patients underwent segmental liver resection, two patients underwent hemi-
hepatectomy and one underwent an open excision of a lingular mass of the lung. 
Pre-operative and post-operative treatment 
Of 59 patients with rectal cancer, 39 (66.1%) underwent neo-adjuvant therapy. Fifteen 
(25.4%) of these received short course radiotherapy and 24 (40.7%) long course chemo-
radiation. Seventy-seven (32.5%) patients of the full cohort received adjuvant 
chemotherapy: 2.6% for stage I, 18.2% for stage II, 72.7% for stage III and 100% for stage 
IV.  
Recurrences 
The median follow-up duration was 61 months (46-81 months) and overall survival rate 
was 68.6%. In total, 59 (24.9%) patients developed disease recurrence, at a median time 
of 14.0 months.  
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Timing of recurrence 
The annual recurrence rates were 9.7% for year one, 7.2% for year two, 3.8% in year 
three, 2.1% in year four and 0.8% for year five and greater (Figure 10). The median time to 
local recurrence was 12.5 months (IQR 8.5-26.0) with a similar time for distant recurrence 
at 14.0 months (IQR 8.0-25.0).  
 
Figure 10. Annual recurrence rates following surgery for colorectal cancer 
Site of recurrence 
The most common site of disease recurrence was the liver (n=25) followed by the lung 





The overall recurrence rate was 26.4% for colon compared with 20.3% for rectal cancer 
(p=0.35); liver recurrences occurred in 11.8% of colon and 6.8% of rectal cancers (p=0.28); 
lung recurrences in 5.6% of colon and 10.2% of rectal cancers (p=0.23) and local 
recurrence occurred in 7.9% of colon cancer and 1.7% of rectal cancer (p=0.09). 
Recurrences are summarised by stage in Table 8.  
 
  
Figure 11. Site of recurrence by site of primary cancer. 
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Table 8. Recurrences (local and distant) by stage and site of primary.   
Disease Free Survival – All Patients 
 In Figure 12, Kaplan-Meier curves show a pronounced decrease in disease free survival in 
the first 24 months, across all four stages. The 5-year DFS by stage were 84.6 % in stage I, 
64.4 % in stage II, 53.1 % in stage III and 30 % in stage IV.  
On univariate analysis, emergency presentation, advanced TNM stage, histological high 
grade, lympho-vascular invasion and peri-neural invasion were significantly associated 
with DFS. Following multi-variate analysis, TNM stage and perineural invasion 
independently predicted disease free survival (Table 9). 
  
Stage Colon (%) Rectum (%) Total (%) 
Stage I 21 18 39 
   Local 0 (0) 0 (0) 0 (0) 
   Distant 0 (0) 2 (11.1) 2 (5.1) 
Stage II 73 17 90 
   Local 8 (10.9) 1 (5.9) 9   (10.0) 
   Distant 7 (9.59) 4 (23.5) 11 (12.2) 
Stage III 77 21 98 
   Local 6   (7.8) 0 (0) 6   (6.1) 
   Distant 21 (27.3) 4 (22.2) 25 (25.5) 
Stage IV 7 3 10 
   Local 0 (0) 0 (0) 0 (0) 
   Distant 5 (71.4) 1 (33.3) 6 (60.0) 
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Table 9. Univariate and multivariate analysis of predictors of disease free survival 
  Univariate Analysis Multivariate Analysis 
  HR (95% CI) p value HR (95% CI) p value 
Emergency  1.63 (0.98-2.70) 0.06 - -  
Stage     
  II 2.60 (1.09-6.21) 0.03 2.50 (1.05-6.00) 0.04 
  III 3.74 (1.60-8.78) <0.01 3.37 (1.43-7.95) <0.01 
  IV 6.00 (2.01-17.88) <0.01 4.97 (1.64-15.08) <0.01 
Mucinous 1.09 (0.61-1.97) 0.77   
High grade 1.69 (1.03-2.77) 0.04 - - 
≥12 LN Yield 1.09 (0.72-1.64) 0.70 - - 
LVI 1.69 (1.11-2.58) 0.02 - - 
PNI 2.21 (1.34-3.65) <0.01 1.79 (1.07-2.99) 0.03 
LN: Lymph node; LVI: Lymphovascular invasion; PNI: Perineural invasion 
 
Overall Survival – All Patients 
There were 74 deaths from all causes giving a 69.8% 5-year overall survival for the cohort. 
The overall survival by stage were, 87.2% in stage I, 76.7% in stage II, 58.2% in stage III and 
30.0% in stage IV. The Kaplan-Meier curves in Figure 13 show that a decline in survival 
occurs after 36 months, particularly in patients with stage IV disease. Stage was the only 
factor on multivariate analysis to be associated with overall survival (Table 10). 
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Table 10. Univariate and multivariate analysis of predictors of overall survival 
  Univariate Analysis Multivariate Analysis 
  HR (95% CI) p value HR (95% CI) p value 
Emergency  1.83 (1.07-3.15) 0.03 -  
Stage     
  II 1.87 (0.71-4.96) 0.21 1.87 (0.71-4.96) 0.21 
  III 3.78 (1.49-9.56) <0.01 3.78 (1.49-9.56) <0.01 
  IV 6.19 (1.96-19.52) <0.01 6.19 (1.96-19.52) <0.01 
Mucinous 1.19 (0.66-2.17) 0.56   
High grade 1.90 (1.12-3.24) 0.02 - - 
≥12 LN Yield 1.05 (0.66-1.67) 0.83   
LVI 1.48 (0.92-2.37) 0.11   
PNI 2.06 (1.18-3.59) 0.01 - - 
LN: Lymph node; LVI: Lymphovascular invasion; PNI: Perineural invasion 
2.4 Results – Pre-Operative CEA 
Seventy-three patients were excluded as they underwent palliative treatment. Of these, 
10 patients were co-morbid with locally advanced disease and 63 patients had widespread 
metastasis (Figure 14). 
Out of 237 patients who underwent surgery with curative intent during the study period, 
139 (58.6%) patients had preoperative CEA measured (Figure 14). This group had a median 
age of 71 years (range 32 to 91 years), 67 (48.2%) were male, 72 (51.8%) female, and 22 
(15.8%) patients had stage I, 55 (39.6%) stage II, 58 (41.7%) stage III and 4 (2.9%) patients 
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had stage IV disease. The overall survival was 70.5%, and disease-free survival 61.6% at a 
median follow-up duration of 61 months (range 46-81 months).  
 
CEA Availabil ity 
Baseline demographics and disease stage were compared between patients with missing 
(n=98) and available (n=139) pre-treatment CEA measurements, to evaluate potential 
selection bias. The two groups did not differ significantly by age, sex, comorbidities, site or 
stage of cancer (Table 11).  A higher proportion of patients with missing CEA data had a 
history of smoking (p=0.02) and underwent emergency surgery (p=0.003) and Kaplan-
Patients diagnosed with colorectal 
adenocarcinoma 2010 to 2012 
(N = 310) 
Palliative treatment (N = 73) 
Curative intent treatment 
(N = 237) 
Pre-treatment CEA Missing 
(N = 98) 
Pre-treatment CEA Available 
(N = 139) 
Colon cancer 
(N = 101) 
Rectal cancer 
(N = 38) 
Figure 14. Flowchart demonstrating patient numbers by CEA availability and primary site 
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Meier curves did not demonstrate a significant difference between the groups for disease-
free survival (Figure 15) or overall survival (Figure 16).  







Age, years  71 (64-77) 71 (63-78) 0.83 
Gender 
  Male 






Co-Morbidities    
  0 57 (58.2) 89 (64.0)  
  1 24 (24.5) 30 (21.6) 0.65 
  2+ 17 (17.3) 20 (14.4)  
Site    
  Rectum 20 (20.4) 39 (28.1) 0.18 
  Colon 78 (79.6) 100 (71.9) 0.18 
Stage   0.79 
  I 17 (17.3) 22 (15.8)  
  II 35 (35.7) 55 (39.6)  
  III 40 (40.8) 58 (41.7)  
  IV 6 (6.1) 4 (2.9)  
Emergency     
  Obstruction 17 (17.3) 9 (6.5) 0.01 





Figure 15. Kaplan-Meier survival curves for disease free survival of patients by pre-treatment CEA 
availability (p=0.72). 
 






Optimum cut-off value 
The median CEA value was 3.5ng/mL (range 0.4-2285ng/mL). A receiver operator curve 
was plotted for CEA against disease free survival and from this an optimum cut-off value 
of 3.0 ng/mL was chosen (sensitivity 0.70, specificity 0.52, area under the curve=0.62, 
p=0.02) which was then used to divide the cohort into two groups, ‘High CEA’ (n=73) and 
‘Low CEA’ (n=65) (Figure 17).  
There were no significant differences in baseline demographics between these groups 
although when pathological characteristics were compared (Table 12), the groups varied 
by site (p=0.05) and stage (p=0.03).  
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Figure 17. Receiver Operator Curve analysis of the ability of pre-treatment CEA to predict disease 




Table 12. Clinicopathological data by pre-treatment CEA. 





Age, years (Median, IQR) 67.5 (63.0-75.5) 73.0 (64.0-79.0) 0.12 
Gender 
  Male 






Co-Morbidities   0.36 
  0 40 (71.4) 49 (59.8)  
  1 9 (16.1) 20 (24.4)  
  2+ 7 (12.5) 13 (15.9)  
Site    
  Rectum 21 (37.5) 18 (22.0) 0.05 
  Colon 35 (62.5) 64 (78.0)  
Stage    
  I 14 (25.0) 8 (9.8) 0.03 
  II 21 (37.5) 34 (41.5)  
  III 18 (32.1) 39 (47.6)  
  IV 3 (5.4) 1 (1.2)   
Emergency      
  Obstruction 2 (3.6) 7 (8.5) 0.25 
  Perforation 1 (1.8) 3 (3.7) 0.52 
 
Out of 38 patients with rectal cancer, 26 (68.4%) received neoadjuvant therapy which was 
in the form of short course radiotherapy in 10 (26.3%) and long course chemo-radiation in 
16 (42.1%). Forty-three (30.9%) colorectal cancer patients received adjuvant 
chemotherapy which most frequently included Capecitabine alone (15.8%), followed by 
Capectitabine and Oxaliplatin (5.0%) and Folinic acid, fluorouracil and oxaliplatin in 
combination (3.6%). Use of neo-adjuvant therapy (p=0.33), adjuvant therapy (p=0.51), and 
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in-hospital morbidity (p=0.86) and in-hospital mortality (p=0.18) did not differ significantly 
between patients with high and low CEA.  
Patient outcomes – Pre-operative CEA 
Kaplan-Meier curves demonstrate that disease free survival (p=0.01) and overall survival 
(p=0.005) were significantly poorer in the ‘high CEA’ group (Figures 18 and 19, 
respectively).  
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Figure 18. Kaplan Meier curves of disease free survival by pre-treatment CEA (p=0.01) 
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Figure 19. Kaplan Meier curves of overall survival by pre-treatment CEA (p=0.005) 
On multivariate analysis, a high CEA (HR 1.99, 95% CI 1.07-3.69, p=0.03) and perineural 
invasion (HR2.74, 95% CI 1.39-5.40, p=0.004) were identified as independent predictors of 




Table 13. Univariate and multivariate analyses for predictors of disease free survival. 
  Univariate Analysis Multivariate Analysis 
  HR (95% CI) p value HR (95% CI) p value 
Emergency  1.93 (0.91-4.09) 0.09 -  
Stage  0.21   
  II 1.70 (0.64-4.57)    
  III 2.53 (0.98-6.56)    
  IV 2.54 (0.49-13.1)    
Mucinous 1.03 (0.49-2.19) 0.93   
High grade 1.50 (0.77-2.92) 0.23   
≥12 LN Yield 1.13 (0.66-1.93) 0.67   
LVI 1.73 (1.00-3.00) 0.05 -  
PNI 3.07 (1.57-6.00) 0.001 2.74 (1.39-5.40) <0.01 
Raised CEA 2.20 (1.20-4.06) 0.01 1.99 (1.07-3.69) 0.03 





On multivariate analysis for overall survival, a high CEA was identified as the only 
independent predictor of poorer disease free survival (HR 3.17, 95% CI 1.46-6.89, p=0.004) 
(Table 14).  
 
Table 14. Univariate and multivariate analyses for predictors of overall survival. 
  Univariate Analysis Multivariate Analysis 
  HR (95% CI) p value HR (95% CI) p value 
Emergency  2.26 (1.00-5.10) 0.05 -  
Stage  0.14   
  II 1.12 (0.39-3.76)    
  III 2.42 (0.84-6.99)    
  IV 2.52 (0.46-13.78)    
Mucinous 1.50 (0.69-3.26) 0.30   
High grade 1.65 (0.79-3.46) 0.18   
≥12 LN Yield 1.05 (0.57-1.94) 0.88   
LVI 1.31 (0.69-2.50) 0.42   
PNI 2.01 (0.89-4.55) 0.09 -  
Raised CEA 3.17 (1.46-6.89) <0.01 3.17 (1.46-6.89) <0.01 








In this study, a recurrence rate of 24.9% was found at 5 years, with a median time-to-
recurrence of 14 months and mortality rate of 31.2%; these findings are comparable to 
the modern International literature 321-331. Recurrence most commonly occurred in the 
liver, followed by lung, with a local recurrence rate of 6.3%. Recurrence was strongly 
linked to disease stage. Stage II patients made up 37.9% of all those undergoing surgery 
with curative intent and had a recurrence rate of 22.2%. Recurrences in stage II patients 
made up 33.9% of all recurrences observed. 
Twenty-five out of 59 (42.4%) recurrences were observed in the first year following 
surgery and 43 (72.9%) within the first two years, with annual recurrence rates decreasing 
sharply thereafter. That the majority of recurrences occur within the first two years post-
operatively is reflected in several guidelines which recommend increased frequency of 
follow-up clinic appointments within the first two to three years, such as those of the 
American Cancer Society, National Comprehensive Cancer Network and European Society 
for Medical Oncology 100, 101, 332. Studies with longer formal follow-up programmes have 
demonstrated low recurrence rates beyond five years also and this includes Seo et al’s 
study of 4,023 patients that revealed 36 (0.9%) recurrences occurred beyond five years 328. 
Our results are consistent with others in demonstrating the liver as the most common site 
of disease recurrence for rectal and colonic primaries combined 321, 322, 324, 326, 333, 334. 
Recurrences in the lung were relatively more common for rectal primaries compared with 
colonic, occurring in 10.2% and 5.6% respectively, although this difference was not 
statistically significant (p=0.28). This pattern is frequently attributed to systemic venous 
drainage of rectal cancers via the pelvic veins 335. Although much less common, we found 
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other sites of disease recurrence to include bone, brain, distant lymph nodes, peritoneum 
and ovary. Whilst we did not observe any recurrences in the spleen, this has also been 
reported previously, albeit infrequently 336.  
We found recurrence rates to range from 5.1% to 60% in stages I to IV and multi-variate 
analysis identified disease stage as a strong independent predictor of overall and disease 
free survival.  
The all-cause mortality rate in this cohort of 31.4% compares favourably to rates of 
approximately 40% reported historically in New Zealand and suggests a continuing trend 
of improving outcome 337-339. Data from the SEER database reveals a five year mortality of 
35.1% although this is not limited to patients undergoing surgery with curative intent 14.  
The proportion of patients receiving adjuvant therapy in this cohort, 32.5%, falls short of 
the 40% reported by Buchwald et al, who have demonstrated a steady increase in the use 
of adjuvant therapy at their tertiary centre between 1993 to 2009 340. The proportion of 
stage III colon cancer patients receiving adjuvant chemotherapy was 58.4% in this cohort, 
which is very similar to 59% reported in the Presentations, Investigations, Pathways, 
Evaluation and Rx (PIPER) project report. Likewise, 34.7% of patients with non-metastatic 
rectal cancer in this cohort compared with 36% in the PIPER project report received 
adjuvant chemotherapy 341. For rectal cancer, 66.1% of patients received some form of 
neo-adjuvant therapy which falls between the national average of 52% reported in the 
PIPER project report and 82% achieved in the 2009 cohort reported by Buchwald et al 340, 
341. This demonstrates variability in the use of neo-adjuvant treatment, some of which may 
represent access to resources. However, the figures presented in this cohort are in 
concordance with other national datasets.  
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We report a very low rate of local recurrence following rectal cancer surgery of 1.7% and 
no patients had both local and distant recurrence. This compares well against modern 
international studies, where rates of 2.4-10% are frequently reported 327. Rectal cancer 
surgery at the unit is performed exclusively by surgeons with subspecialist training and 
may go toward explaining the low local recurrence rates and indeed the one case of local 
recurrence was in a patient that needed an APR and declined surgery for 15 months. This 
also reflects a large improvement from rates in excess of 20% reported in the literature 
prior to the introduction of total mesorectal excision, adjuvant therapies, multidisciplinary 
team discussion and surgical subspecialisation 338, 342.  
Although the findings of this study were not novel to the field of Colorectal Surgery, the 
outcomes observed in this retrospective cohort study were comparable to those reported 
in the contemporaneous surgical literature. This helps to establish the study population as 
appropriate for further prognostic study. 
Prognostic Value of Pre-Operative CEA 
We found that 58.6% of patients had a pre-treatment CEA measured and this was more 
likely to be performed in the elective setting compared to emergencies. Given the high 
proportion of missing data, pre-operative CEA was excluded as a co-variate in survival 
analyses of the entire cohort. Using ROC curve analysis to select an optimal cut-off value, 
we found that a raised pre-treatment CEA was an independent predictor of disease free 
and overall survival after a median follow-up period of 61 months. Our observation that 
CEA was an independent predictor of survival is consistent with the findings of other 
studies 130, 343-347. Becerra et al analysed data from 137,381 patients from a USA-based 
national database and found a raised pre-treatment CEA to be predictive of all-cause 
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mortality (HR 1.62, 95% CI 1.53-1.74, p<0.0001) independent of stage in stage I to III colon 
cancer130. Tarantino et al demonstrated pre-treatment CEA to be predictive of overall 
survival (HR 1.46, 95% CI=1.02-2.08, p=0.044) and cancer-specific survival (HR 3.28, 95% 
CI=1.78-6.03, p<0.001) in 1932 patients with stage I rectal cancer 346. Additionally, Kim et 
al found pre-treatment CEA to predict disease free survival and overall survival in patients 
with stage III colon cancer following curative resection with adjuvant chemotherapy 347. 
Whilst these large studies suggest a prognostic role for CEA within subgroups of colorectal 
cancer patients at a population level, our study reveals an effect that is observable across 
disease site and stage at an individual level and this may be useful in informing 
personalised treatment decisions. 
A number of methods have been utilised to select a cut-off value for CEA in the literature. 
Although seemingly arbitrary, 5ng/mL has been used by many groups, almost as 
convention. Other investigators have used reference ranges given by their Institution’s 
laboratory and others still have determined optimal cut-off values based on ROC curves, 
as was implemented in the present study. It is noteworthy that the cut-off value of 3.0 
ng/mL selected in this study is lower than the 5ng/mL value proposed by AJCC and that 
conventionally used in the literature 127, 346, 348, 349. Individualised cut-off values have been 
used by Reiter et al, in which 4ng/mL was taken, and by Jeon et al, who identified 5.5, 4.8 
and 3.5ng/mL as optimum cut-off values for TNM stages I, II and III, respectively 350, 351. 
Kim et al found a CEA above 3.0ng/mL independently predicted DFS and OS in stage III 
colon cancer 347. Taken together, these results suggest that a relationship between pre-
operative CEA and prognosis does exist, but that its implementation in clinical practice is 




The current study has a number of limitations to acknowledge.  
From the outset, continuous variables, such as pre-operative CEA, were dichotomised. 
This approach was selected in order to allow simple risk-stratification and to produce 
results that could be compared against existing studies, many of which have taken the 
same approach. However, it must be noted that potentially valuable prognostic 
information may be lost by simply stratifying the cohort into “high” or “low”. An 
alternative approach would be to perform linear regression, although this assumes a 
linear relationship between variable and outcome. Additionally, unless the median is 
taken as the cut-off point, invariably the two groups become unequal in size. In the case of 
the present study, 82/138 (59.4%) had a raised CEA. In practical terms, a CEA of less than 
3.0ng/mL would be more clinically useful in identifying a low-risk population than treating 
all patients with a raised CEA as high-risk, which may in turn result in over-investigation or 
–treatment.  
A further limitation to the study is in determining an optimal cut-off value for pre-
operative CEA based on the same sample that is being studied. This method has the 
potential to over-estimate the effect of CEA on prognosis by increasing Type I errors. A 
means to address this could be by cross-validation. This is where the cohort is divided 
randomly into two groups. One sub-group is then used to determine the optimum cut-
point, which is then applied to the second sub-group. The disadvantage to this approach is 
in reducing the statistical power by halving the size of the study sample. 
Histological grade and lymphovascular invasion failed to be identified as independent 
predictors of disease free survival in this study, despite their role as prognostic factors 
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being well-established in the literature to the point of being considered high-risk features 
of stage II CRC when selecting patients for adjuvant chemotherapy 100, 101, 332. Furthermore, 
the TNM stage was identified as an independent predictor of disease free and overall 
survival when the entire cohort was examined, but was not identified as a predictor of 
either in the sub-group of patients with available CEA data. This brings into question the 
validity of the second part of this study given that TNM stage is considered the strongest 
and most widely studied prognostic indicator in this setting. However, it should be noted 
that, given the extent of missing CEA data, the cohort size was significantly reduced in size 
with only four out of ten patients with stage IV being included. Therefore, it is more likely 
that the four TNM stages were not adequately represented in the second part of this 
study, than pre-operative CEA being a stronger predictor than TNM stage.  
Another limitation is that the observed recurrence rates may have been influenced by 
adherence to the post-operative surveillance protocol. Therefore, had the outcomes 
reported in this study been discordant with other National data, evaluation of the 
compliance with post-operative surveillance would have been warranted. On the other 
hand, some studies have failed to demonstrate an improved rate of recurrence detection 
with increasing surveillance intensity 352, 353. This includes Snyder et al’s retrospective 
study of 8529 patients across 1175 hospitals353. The hospitals were determined to be 
either high- or low-intensity surveillance facilities based on the number of surveillance 
scans or CEA tests carried out. No significant difference in time-to-detection of recurrence 






This study found the overall recurrence rates at the host institution to be comparable to 
International standards, with rectal cancer recurrence rates that were found to be lower. 
Recurrences were most commonly observed at distant sites and within two years of 
surgery. It is possible that these early, distant recurrences indicate the presence of occult 
metastasis at the time of surgery, in a subset of patients. In turn, circulating biomarkers 
may provide the sensitivity required to detect such patients and pre-operative 
carcinoembryonic antigen (CEA) was evaluated as part of this study, given it is a readily 
available test in clinical practice. We found that a raised pre-treatment CEA was predictive 
of a poorer overall survival and disease-free survival independent of stage. This 
corroborates findings within the wider literature and CEA remains the single most studied 
circulating biomarker in the field of colorectal cancer prognosis. Unlike pathological 
staging criteria such as lymph node involvement, circulating biomarkers may provide 
prognostic information that is available to the patient and clinician at the outset. This in 
turn may help to inform and guide major treatment decisions at an earlier time-point.  
As outlined in the first chapter, a growing appreciation of the link between systemic 
inflammation and outcomes in colorectal cancer is being made through both experimental 
data and clinical studies. Cytokines, through a number of systemic inflammatory 
pathways, may act on tumour and host cells to promote tumour growth and 
dissemination.  In the next chapter, a systematic review of the literature will be carried 











Prognostic value of multiple cytokine 
analysis in colorectal cancer: 




3.1 Introduction  
In Chapter Two, CEA was shown to provide prognostic information in terms of disease free 
and overall survival. While CEA remains the most widely studied circulating prognostic 
biomarker in colorectal cancer, the mechanism for this association remains poorly 
understood. In contrast to this, experimental data suggests circulating cytokines act 
through a range of pathways involved in tumour progression (Chapter One). This has led 
to a great deal of interest in studying the prognostic value of circulating cytokines in 
colorectal cancer. In 2014, a systematic review was performed by Liu et al of prognostic 
studies of circulating biomarkers in colorectal cancer. 354. They included 49 studies 
studying 44 prognostic markers but found that only 21 markers were studied in two or 
more studies. Although their review was not exclusive to inflammatory cytokines, but 
included tumour markers as well, their findings demonstrate the lack of heterogneity in 
the cytokines tested in prognostic biomarker studies. 
Despite this, a number of studies have found particular cytokines to show promise as 
potential prognostic markers, including interleukin-6,(IL-6) 298, 302, 355-357 TNF alpha 
(TNFα)302, 358, 359 and interleukin 1β(IL-1β)302, 360. Many of these studies have evaluated 
individual biomarkers and have found them to weakly predict prognosis. However, 
experimental data also shows individual cytokines to participate in numerous and 
sometimes opposing pathways along disease progression 193, 211, 361. Therefore, it is 
possible that characterising inflammatory state by combining multiple cytokines may be a 
more robust approach than measuring a single inflammatory marker.  
Aims 




❖ To perform a systematic review of the literature evaluating the prognostic value of 
multiple cytokine analysis in colorectal cancer 
❖ To determine whether a composite inflammatory score derived from multiple 
peripheral cytokine markers provides prognostic value in colorectal cancer 
 
3.2 Methods  
Search strategy 
The methodology of this systematic review followed Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines 362, 363. Searches of 
the MEDLINE, EMBASE and Scopus databases were performed on 30th August 2017 using a 
search strategy that included the terms ‘colon, rectal, colorectal cancer’, and ‘cytokine, 
cytokines’ and ‘outcome, prognosis, survival, mortality, death, recurrence’. The results 
were limited to English language, human studies and articles published since the year 
2000; studies prior to this were not included due to outdated clinical practices. The 
corresponding author was contacted in instances where only the abstract was available 
and the study was subsequently excluded if the available data was incomplete or could 
not be provided. 
Eligibil ity criteria 
Studies examining the association between baseline, peripherally circulating cytokine 
levels and prognosis in patients with colorectal adenocarcinoma were eligible. Studies 
were excluded if two or fewer cytokines were evaluated, or the primary outcome 




Method of study review 
Data was collected in duplicate by two independent reviewers and a third reviewer 
consulted on areas of differing opinion. Quality assessment of eligible studies was 
performed by assessing the risk of bias in the six domains described by Hayden et al364. 
These were, ‘study participation’, ‘study attrition’, ‘prognostic factor measurement’, 
‘outcome measurement’, ‘study confounding’, ‘statistical analysis and reporting’. Two 
reviewers assessed each study independently and each domain was given a score of 0 for 
high risk, 1 for moderate risk and 2 for low risk of bias. Instances of differing opinion were 
resolved through discussion with a third reviewer available to adjudicate if necessary. 
3.3 Results  
Description of Studies. 
Seven studies were included in this review 293, 302, 306, 365-368 after screening 570 records, the 
number of records screened out by stage are given with the reasons in the flowchart 
(Figure 20).   
Overall, the quality of the studies was poor to moderate with QUIPS scores ranging from 
one to six out of twelve (Table 15). Of the six domains assessed, the studies performed 
well in prognostic factor measurement with a combined score of ten out of fourteen 
across the seven studies. The authors often reported standardised methods of blood 
sampling and detailed the assay methods performed. In contrast the studies performed 
poorly in the ‘study participation’ domain, with a total score of two. The main reasons for 
this were small sample sizes, retrospective study design and studies that were limited to 





Figure 20. Flowchart demonstrating study selection for inclusion in systematic review. Modified 
from the PRIMSA statement 369. *Authors of abstracts were contacted. 
Records identified through 
MEDLINE database searching 
(n=840) 
Records identified through 
EMBASE and Scopus  
(n=398) 
Records screened on title 
or abstract 
(n=570) 
Records after duplicates removed 
(n=570) 




354 not relevant  
132 fewer than three 
cytokines 
43 not colorectal cancer 
17 not prognosis or in vitro 
studies 
Articles found through 
reference lists 
(n=5) 





3 < 3 cytokines 
2 full text not available 
 
Full-text articles excluded 
(n=17) 
8 review or not prognosis 
7 < 3 cytokines 


































































































Five of the seven studies included patients of all stages (Table 16) 293, 302, 306, 367, 368. Two of 
these included all patients attending hospital with a histological new diagnosis of 
colorectal adenocarcinoma302, 368 and three studies included only those undergoing 
surgery293, 306, 367. The remaining two studies included stage IV patients only365, 366 although 
a clear rationale for looking exclusively at this sub-group was not given, citing evidence 
linking circulating cytokines to prognosis in colorectal cancer across patients of all 
stages207, 298, 370. 
Two studies were prospective in design306, 367, two retrospective302, 366 and the study 
design was not stated in three studies293, 365, 368.  The sample sizes were relatively modest 
ranging from 46 to 205 participants and all seven studies were conducted at separate, 
single institutions. None of the investigators reported an attempt to perform power 
calculations to arrive at their intended sample size. Five of the seven studies had a mean 
or median follow up duration of approximately five years.  
The number and selection of cytokines measured varied across the studies and whilst IL-6 
was evaluated in all seven and IL-8 evaluated in six studies293, 306, 365-368 based on existing 
literature, lesser known markers were included in some of the, particularly larger, panels 
tested365, 366. The Chen et al (2015a365 and 2015b366) studies  utilised commercially 
available panels including 39 and 51 cytokines, providing justification for only a fraction of 
the markers tested in the form of existing scientific and clinical evidence. All seven studies 
measured cytokine levels in pre-treatment samples, with no comparisons to post-











































































The primary end-point measured was overall survival in four studies, and in the remaining 
three studies, was based on the incidence of disease recurrence302, 306, 367. The study by 
Chang et al referred to this as the progression-free survival, which was defined as ‘no 
imaging or pathological evidence of disease progression’302. The study included patients of 
all stages and the treatments undertaken by participants were not stated in the report. 
Vӓyrynen et al measured the Disease Free Survival (DFS) but did not provide a definition of 
this outcome in the manuscript306 and Di Caro et al measured DFS defining their events as, 
‘any event of local tumour recurrence or any metachronous distant-organ metastases’367. 
For simplicity, the results of these three studies have been grouped together as ‘disease 
free survival’ in Table 17.  
Di Caro et al utilised computed tomography, ultrasound and chest radiographs according 
to a common protocol, and was the only study to report a standard approach to the follow 





Table 17. Summary of results of studies included in systematic review. 
Independent Predictors of Overall Survival 
Study Prognostic marker Hazard Ratio (95% CI) P value 
Kaminska 2005368 sTNF RI   RR 3.10 (Relative Risk) 0.009 
Shimazaki 2013293 IL-6 HR 4.1   (1.20-13.98)     0.024 
Chen 2015a*365 Flt-3L  HR 2.19 (1.29-3.71) 0.004 
 MDC HR 1.89 (1.29-2.77) 0.001 
 IL-2 HR 1.71 (1.14-2.56) 0.009 
 IL-8 HR 2.06 (1.28-3.32)   0.003 
 MIP-1β  HR 1.69 (1.11-2.59) 0.015 
Chen 2015b*371 †CS HR 2.29 (1.51-3.48) <0.001 
 NLR-CS HR 2.09 (1.59-2.76) <0.001 
Vӓyrynen 2016306 IFNɣ HR 0.47 (0.24-0.90) 0.022 
Independent Predictors of Disease Free Survival 
Study Prognostic marker Hazard Ratio (95% CI) P value 
Chang 2016302 ††CS    HR 9.20   (1.21-69.70) 0.036      
Di Caro 2016367 IL-8  HR Not available          <0.001 
 PTX3  HR 9.64   (2.24-41.42)   <0.002 
 VEGF  HR Not available <0.001 
 ††† CS HR 16.21 (3.56-73.84) <0.001 
Vӓyrynen 2016306 CCL4   HR 0.38   (0.15-0.92) 0.033 
 
No cytokines identified as independent predictors of Cancer Specific 
Survival. 
 
sTNF R1: Soluble tumour necrosis factor receptor 1, Flt-3L: FMS-like tyrosine kinase, MDC: 
Macrophage-derived chemokine, IL: Interleukin, MIP: Macrophage inflammatory protein, CS: 
Cytokine Score, NLR: Neutrophil-lymphocyte ratio, IFN: Interferon gamma, PTX: Pentraxin, 
VEGF: Vascular Endothelial Growth Factor, CCL: C-C motif chemokine ligand.  
*Stage IV only 
† Cytokine score based on IL-6,IL-8, IL-2Ra,IL-18, HGF, M-CSF, VEGF-A, MIP-1b, GROa, MIF, 
SCGF-b, TRAIL, Amphiregulin, EGF, Epiregulin, HB-EGF, Tenascin, TGF-a, ICAM-1. 
†† Cytokine score based on IL-6, IL-1β and TNFα. In patients with CRP<5 mg/L 





Individual cytokines and Overall Survival.  
Five studies measured overall survival as the primary outcome293, 306, 365, 366, 368. On 
univariate analysis, Chen et al (2015a) found 17/39 (43.6%)365, Kaminska 6/14 (42.8%)368, 
Shimazaki 1/6 (16.7%)293 and Vӓyrynen found none of 13 cytokines306 to be associated 
with OS whilst Chen et al (2015b) did not report the results of univariate analysis. On 
multivariate analysis, Chen et al (2015a) found 5/39 (12.8%)365, Chen et al (2015b) none of 
51366, Kaminska et al none of 14368, Shimazaki et al 1/6 (16.7%) 293 and Vӓyrynen found 
1/13 (7.7%)306 individual cytokines measured to independently predict OS. All five studies 
included IL-6 in their panel and only one of these identified this cytokine as an 
independent predictor293. All five studies included IL-8 and none of them identified it as a 
predictor (Table 17). 
One study found that raised levels of interferon gamma (IFNγ) were predictive of a 
favourable overall survival306. IFNγ was also included in the panel of one other study - 
which was limited to stage IV patients - and did not show a significant association with OS 
on univariate analysis and therefore was not included in multivariate analysis365. One 
other marker, CCL4, was identified across the seven studies to predict improved survival 
with increased levels 306. 
Individual cytokines and Disease Free Survival.  
Three studies measured disease free survival. Di Caro et al found 3/6 (50%) 367, Chang et al 
2/3 (66.6%)302 and Vӓyrynen found 1/13 (7.7%) 306 cytokines to be associated with DFS on 
univariate analysis. On multivariate analysis, Di Caro et al found 3/8 (37.5%),367 Chang et al 
none of three302 and Vӓyrynen found 1/13 (7.7%)306 individual cytokines to predict DFS.  




an independent prognostic indicator. IL-8 was found to independently predict DFS in one 
of the two studies that measured this cytokine 367 (Table 17). 
Combined ‘Cytokine Scores’.  
Four studies combined multiple cytokine levels into a composite score and varied in the 
number and selection of cytokines as well as the way in which they were combined302, 365-
367. 
Di Caro et al incorporated three cytokines that were independent predictors of DFS on 
multivariate analysis367. Using cut-off values identified on ROC curve analysis, a ‘high’ 
score was given if all three markers were raised, a ‘low’ score for patients where all three 
markers were low and a ‘medium’ score for the remaining patients. This score improved 
upon the prognostic value of Pentraxin-3, an acute phase protein related to C reactive 
protein372. The hazard ratios were not available for the remaining two cytokines as all nine 
events occurred in the patients with raised levels. This meant that a direct comparison 
between individual cytokines and the composite cytokine score was not possible. 
Chang et al measured three cytokines and incorporated all three into the cytokine score 
despite only two of which showed a significant association with OS on the Chi squared 
test302. Patients were assigned a cytokine score of zero to three based on the number of 
cytokine values that were above the median. This cytokine score outperformed individual 
cytokine levels in patients with a CRP of less than 5mg/L although in patients with CRP 
above 5mg/L, individual cytokines and the composite cytokine score were not 
independent predictors of DFS. The investigators did not justify a rationale for dividing 
their cohort into high and low CRP groups but did propose cytokine intensity as an 




Chen et al (2015a) included 17 cytokines that were predictive of overall survival, on 
univariate analysis, into their cytokine score.365 The investigators assigned each cytokine a 
weighted score, based on their hazard ratio on cox proportional regression. The optimum 
cut-off value for the cytokine score was then identified from Receiver Operator 
Characteristic (ROC) curve analysis to dichotomise the variable into high and low. The 
investigators did not evaluate their score against important co-variates such as patient 
and tumour characteristics in a multivariate model but did report a sensitivity and 
specificity in predicting OS of 0.833 and 0.737, respectively. This out-performed all 
individual cytokines in its prognostic accuracy.  
Chen et al (2015b) identified 19 cytokines that correlated with neutrophil-lymphocyte 
ratio and incorporated them into their cytokine score366. Each patient was given a score 
based on the sum of the Z scores of the selected cytokines. The Z score was defined as the 
difference of the average and individual cytokine level divided by standard deviation of 
log2-transformed value. The cohort was then divided into high or low cytokine score 
groups using the median score as a cut-off which predicted OS. Individual cytokines were 
not entered into a cox proportional regression analysis and were therefore not compared 
directly against the composite cytokine score.  
All four studies that included a cytokine score concluded that the scores were 
prognostic302, 365-367. However, only Chen et al (2015b) made a direct comparison between 






3.4 Discussion  
This systematic review found that only seven studies evaluated multiple cytokines after 
570 records were screened. A high degree of heterogeneity was found between the 
studies with respect to the patient groups evaluated and outcomes measured. They were 
also limited by small sample sizes and included those taking an opportunistic look at 
retrospective cohorts, contributing to poor to moderate quality scores. The use of large, 
pre-manufactured cytokine panels was sometimes chosen over a targeted investigation of 
smaller panels of cytokines with known prognostic value and the results of individual 
cytokine analysis yielded inconsistent findings. In contrast to this, a sub-set of studies 
combined multiple cytokines to produce a composite cytokine score and these were more 
consistently found to be predictive, although different methods were used to produce 
these scores. Furthermore, no reports were found to evaluate different methods of 
producing a composite score.  
The link between inflammation and cancer is considered such that inflammation has been 
named as one of the hallmarks of cancer 373. This is demonstrated by the up to twenty-fold 
increase in the lifetime risk of CRC in patients with inflammatory bowel disease, and whilst 
colitis-associated cancer (CAC) accounts for only 2-3% of CRCs, inflammation also plays an 
important role in sporadic cancers374, 375.  On the cellular level, inflammation within the 
tumour microenvironment facilitates malignant cell survival, growth and progression by 
the actions of inflammatory cytokines acting through a variety of pathways including the 
IL-6/JAK/STAT pathway, which is considered key193, 376. Systemic processes are also 
thought to play an important role both in recruiting immune cells from the bone marrow 




Given the emerging role of systemic inflammation in colorectal cancer, it is clinically 
relevant to evaluate the prognostic value of circulating inflammatory cytokines.  
The ability to predict prognosis is of value to clinicians largely by informing treatment 
decisions. More aggressive treatment strategies, namely the use of adjuvant 
chemotherapy following surgical resection may reduce the likelihood of recurrence but 
results in exposure to potentially harmful side effects and must be administered 
selectively to those patients considered high-risk. At present, the pathological TNM stage 
provides the most powerful means of risk-stratifying patients but uncertainty remains, 
particularly in patients with stage II disease who have a 5-year recurrence rate of 
approximately 20%377, 378. Two of the included studies were limited to stage IV patients 
only and a clear rationale for this was not included in the reports365, 366. The results of 
these studies do not therefore contribute to answer the question of whether multiple 
cytokines measurement can provide prognostic information that may be used to inform 
treatment strategy. The two studies limited to stage IV patients also contained variation in 
the treatment regimes received by participants. In the Chen et al’s (2015b) study366, 39 
patients received fluorouracil, irinotecan and bevacizumab as part of a phase II clinical trial 
and the treatment undertaken by the remaining 166 patients was not described379. The 
patients included in the other study by Chen et al (2015a) all underwent systemic 
chemotherapy as their primary treatment and 19 patients underwent partial liver 
resection, suggesting the cohort included patients undergoing a palliative as well as radical 
treatment strategy365. This heterogeneity in study populations diminishes the 




The sample sizes were relatively small, ranging from 46 to 205. Furthermore, power 
calculations were not reported in any of the studies of which only two were prospective in 
design. The likelihood of type II error may also have been increased by introducing an 
excessive number of co-variates into the multivariate analyses; a widely accepted rule of 
thumb being a minimum of ten events being required per variable 380. Recently, calls have 
been made to relax this rule in certain situations although this is mainly applicable to tests 
of sensitivity rather than prognostic studies 381. In addition to the number of variables 
included, the variables themselves are important to consider.  
Given that the TNM classification system is widely used to inform treatment strategies, 
this provides an ideal benchmark to compare cytokine profiles against, yet three studies 
did not include TNM stage as a co-variate in multi-variate analysis. In addition to this, 
cytokine levels have been shown to vary with stage in clinical studies and for these 
reasons, all prognostic studies of cytokine levels should control for this variable 382. 
Although overall survival is considered the gold standard outcome in prognostic studies, 
disease free survival is also an important outcome to measure and is of clinical interest as 
it reflects disease recurrence. Three of the studies included in this review reported disease 
free survival as the primary outcome although it is important to acknowledge that the 
definition of this outcome varied between them302, 306, 367.  Additionally, a systematic 
review by Punt et al included 52 studies of adjuvant treatment in colon cancer and found 
wide variation in the definition of the endpoints used and the starting point for measuring 
time to events320. This variation in the end-point definitions used must be taken into 




All seven of the included studies cited evidence for an overlapping selection of cytokines, 
frequently including IL-6, IL-8, IL-1β and TNFα, linking systemic inflammation and outcome 
in colorectal cancer to justify the rationale of their study and yet, in contrast, varied widely 
in the number and selection of cytokines included in the panels they went on to study 207, 
370, 383. Studies including the lesser known cytokines in their panels were often those 
implementing multiplex cytokine assays using commercially available, pre-manufactured 
cytokine panels365, 366. This approach resulted in a generally low-yield in identifying novel 
biomarkers, one such example of which is Fms-related tyrosine kinase 3 ligand (Flt-3L), 
shown to independently predict overall survival by Chen et al (2015a)365. Flt-3L is a growth 
and differentiation factor generally associated with haematopoiesis and has been found to 
predict poor prognosis in acute myeloid leukaemia although its prognostic value in 
colorectal cancer has not otherwise been reported384, 385.  
Two cytokines with a more established prognostic role in colorectal cancer are IL-6 and IL-
8. Whilst these cytokines were included in the majority of panels tested, they were only 
identified as independent predictors in two of the studies 299, 307. A possible explanation 
for this is that the predictive power of individual cytokines negate each other due to the 
high level of co-variance between them. This is especially true of studies including multiple 
cytokine levels each as co-variates in multivariate analysis.  
The four studies that combined multiple cytokine values into a single score all utilised 
different methods. The question of which cytokines to include is the first consideration 
and Di Caro et al’s approach of selecting those cytokines that were predictive of the 
endpoint independent of stage seems logical367. In contrast, Chang et al’s inclusion of a 




the predictive power of their combined score302. The cut-off values used for individual 
cytokines were either taken as the median, having the advantage of dividing the cohort 
into equal groups, or were identified through ROC curve analysis. The latter approach is 
preferable where the data is skewed and this has often been shown to be the case with 
inflammatory cytokine levels in colorectal cancer populations 382, 383. Individual cytokines 
were weighted according to effect size in the scores used by Chen et al (2015a) and Chen 
et al (2015b)365, 366. This approach acknowledges the finding that some cytokines are more 
powerful predictors of outcome than others, a theme echoed in the results of each of the 
studies included in this review as well as many within the wider literature. The finding that 
two cytokines, IFNγ and CCL4, were found to predict improved rather than worsened 
survival, in contrast to the remaining prognostic cytokines, only emphasises the need to 
consider the differential relationships between cytokine value and outcome when 
formulating a combined score. While the data suggests a multi-marker approach may be 
useful, no real guidance is provided on how to combine them. 
Limitations 
The main limitation of this study pertains to the exclusion of studies measuring fewer than 
three cytokines. By doing so, the validity of comments drawn on the prognostic value of 
individual cytokines are impeded by a significant selection bias. The number and breadth 
of studies into the prognostic value of single cytokine markers, apparent from an initial 
search of the existing literature as well as the review carried out by Liu et al354, suggested 
that encompassing them all into a systematic study would be unlikely to be of great value. 




review. However, the study could have been improved by including studies measuring two 
cytokines, some of which may have utilised a combined score. 
It is noteworthy that, while this study may have been useful in drawing general 
conclusions about the current literature, the data fell far short of allowing any pooled 
analysis to be performed.  Ideally to do this, the raw data from a number of studies 
demonstrating low heterogeneity between cohorts would need to be pooled into a single 
Cox proportional hazard model including potentially confounding variables. Additionally, 
the combined cytokine score would have to be composed of the same cytokines and by 
the same method in each of the included studies. The extent and quality of the available 
reported data did not allow such an analysis but could be performed in the future if data 
availability allows. 
3.5 Conclusion 
This review demonstrates a paucity and heterogeneity of studies examining the prognostic 
value of combining circulating cytokine markers in CRC. There is therefore a need for well-
designed prospective studies evaluating a panel of cytokines that is reasonable in number 
and justified in their inclusion.  
From this review, prognostic studies evaluating panels of multiple cytokines are relatively 
ineffective in identifying novel biomarkers and inconsistent in validating more established 
predictors individually. Despite these forthcomings, there may be some promise in 










Circulating cytokine profiles  






As outlined in Chapter One, systemic inflammation has been implicated in a number of 
pro-metastatic cellular pathways193, 232. These include systemic-signalling between the 
primary tumour and pre-metastatic or metastatic sites that enhance invasion, 
intravasation and metastatic colonisation232. In the previous chapter, a systematic review 
was performed evaluating the prognostic value of multiple cytokine analysis. Here, the 
combination of multiple markers tended to provide additional prognostic information to 
disease stage alone. However, one of the major design flaws in the included studies was 
the inclusion of large panels of pre-manufactured panels of cytokines, some of which had 
little or no previous evidence linking them to colorectal cancer progression. Although the 
systematic review was not directly useful in selecting the cytokines of interest for the 
present study, it informed our approach of testing a small panel of deliberately selected 
markers. Four cytokines were selected on the basis of having an established link with CRC 
progression, from experimental data.  
Interleukin-6 is a pleotropic inflammatory marker and has demonstrated roles in tumour 
progression through cancer cell survival386, promoting angiogenesis213 and accumulation 
of MDSCs within tumours387. Interleukin-8 is a chemokine involved in neutrophil 
mobilisation to tumours which in turn promotes tumour progression388. Studies in CRC cell 
line models have demonstrated IL-8 to promote tumour growth and metastasis207. TNF-α 
promotes MDSC survival389 and triggers proliferation of intestinal epithelial cells and CRC 
cell lines by acting on the TNFR2 receptor 390. Interleukin-1β is expressed by tumour 
associated macrophages197 and neutrophils196 and may act directly on tumour cells to 




For a marker to have prognostic value, we would expect a clear difference in the levels of 
that marker between healthy controls and any colorectal cancer and to show a difference 
between those with and without metastatic disease. CEA and CRP are widely studied 
circulating prognostic biomarkers in CRC and were therefore used for comparison against 
our chosen cytokine panel 298, 391-393. 
Aims 
The aims of this study are: 
❖ To compare baseline levels of plasma IL-6, IL-1β, TNFα and IL-8 between the three 
groups: healthy control, stage II and stage IV CRC. 
❖ To compare cytokine profiles with C-reactive protein (CRP) and carcinoembryonic 
antigen (CEA) 
❖ To utilise a combined score that optimises sensitivity and specificity to differentiate 
between healthy controls, localised and metastatic CRC. 
4.2 Methods 
Patient selection. 
Patients were recruited prospectively into this study from Wellington Hospital, New 
Zealand over a sixteen-month period between October 2016 and February 2018. Disease 
stage was assigned according to the 8th edition of American Joint Committee on Cancer 
guidance 1. Clinical data were de-identified and stored securely on the University server 






Healthy control participants were enrolled from elective endoscopy lists immediately prior 
to undergoing a colonoscopy that was requested on the suspicion of lower gastrointestinal 
malignancy. Patients were excluded if any evidence of inflammation or malignancy was 
detected and were also excluded if they had significant comorbidities including chronic 
inflammatory conditions or synchronous malignancy. 
Stage II Patients 
Patients were recruited into the stage II group on the basis of radiological staging. Rectal 
cancer patients underwent pre-operative MRI pelvis and CT chest abdomen and pelvis, 
and colon cancer patients underwent pre-operative CT chest, abdomen and pelvis alone. 
Imaging was reviewed by two Consultant Radiologists. For colon cancers, staging was 
confirmed postoperatively by pathology.  
Stage IV Patients 
Consecutive patients presenting with metastatic colorectal cancer at diagnosis were 






Exclusion criteria were:  
• age below 18 years 
• emergency presentation 
• chronic inflammatory conditions including inflammatory bowel disease 
• other synchronous primary malignancy 
• colorectal cancer other than adenocarcinoma 
• use of immunosuppressive therapy including oral corticosteroids.  
Ethics 
All patients recruited into this study gave their written informed consent and ethics 
approval was granted by the Health and Disability Ethics Committee (HDEC ref: 
18/CEN/138). 
Plasma sample collection and storage. 
After written consent was obtained, pre-treatment venous blood samples were 
withdrawn from patients in the outpatient setting. Blood withdrawal was performed in 
the morning where possible in a non-fasting state and within four weeks of initial 
treatment. In instances when a delay to initial treatment occurred, a repeat sample was 
taken. In patients undergoing neo-adjuvant therapy, blood samples were withdrawn prior 
to any treatment commenced. Twenty millilitre venous blood specimens were withdrawn 
using a 23G BDTM vacutainer blood collection set into sodium citrate vacutainer tubes after 
discarding the first 5 mL. Venepuncture was preferentially performed from the antecubital 




minutes. Haemolysed samples were discarded. Plasma was stored at -80 degrees Celsius 
for a maximum of twenty-four months. No plasma samples underwent more than two 
freeze-thaw cycles prior to analysis. 
Cytokine assays. 
All assays were performed within twenty-four months of sample collection and in two or 
fewer freeze-thaw cycles. Levels of IL-1β, IL-6, IL-8 and TNFα were quantified from the 
plasma using commercially available sandwich ELISA kits specific for each cytokine 
(Invitrogen, ThermoFisher Scientific) as per the manufacturers instructions. Absorbances 
were measured using the “Multiskan GO” (Thermo Scientific) specialised 
spectrophotometer. The detection limits were IL-6: 2-200 pg/mL, IL-1β: 2-150 pg/mL, IL-8: 
2-250 pg/mL and TNFα: 4-500 pg/mL.  
Blood obtained at the same venepuncture were also sent to the clinical diagnostics 
laboratory at Wellington Hospital where the following were measured, CEA (Roche Cobas 
e601, reference range <3.5 µg/L) and CRP (Roche Cobas 8000, reference range <6 mg/L).  
Statistical analysis 
Statistical analysis was performed as described in Chapter Two (2.2). In addition to this, 
cytokine markers were compared using the area under the curve (AUC) on receiver 
operator curve (ROC) analysis. ROC curves were plotted for each marker’s ability to 
discriminate between controls versus stage II, stage II versus stage IV and controls versus 





IL8-CEA combined score 
IL-8 and CEA values were log-transformed and expressed as a fraction of the highest value. 
This gave a score of zero to one for IL-8 and for CEA, which were then combined to 
produce a sum of zero to two.  
4.3 Results 
A total of sixty patients were included in the study across three groups: control (n=19), 
stage II (n=22) and stage IV (n=19). The mean age was 65.9 years (range 29-85) with 33 
(55.0%) males and 27 (45.0%) females. By ethnicity, 53 (88.3%) were European, 4 (6.7%) 
Maori and 3 (5.0%) other. The median body mass index (BMI) was 28.2 kg/m2 (IQR, 25.0-
31.7). There was a lower proportion of patients with ischaemic heart disease in the stage 
IV group compared with controls (p=0.05) and this was found to be the only patient 





Table 18. Demographics of patients included in prospectively recruited cohort, by disease status 
(Control, Stage II and Stage IV).  
 
Control  
n= 19 (%) 
Stage II  
n=22 (%) 




Mean +/- SD 
68.0 ± 12.0 66 ± 12.0 63.0 ± 12.0 0.45 
Gender 
    Male 
    Female 
 
7      (36.8) 
12    (63.2) 
 
15     (68.2) 
7       (31.8) 
 
11    (57.9) 
8      (42.1) 
0.13 
Ethnicity 
    European 
    Non-European 
 
19    (100) 
0       (0) 
 
19     (86.4) 
3       (13.6) 
 
15    (78.9) 






28.2 (24.8-32.4) 29.6 (26.9-33.1) 27.0 (23.7-29.8) 0.09 
Current smoker 0       (0) 2       (9.1) 4      (21.1) 0.10 
IHD 4       (21.1) 1       (4.5) 0      (0) 0.05 
DM2 3       (15.8) 3       (13.6) 3      (15.8) 0.98 
Aspirin  6       (31.6) 5       (22.7) 2      (10.5) 0.29 
BMI: body mass index, IHD: ischaemic heart disease, DM2: type two diabetes 








Nine of the 19 control patients had polyps on colonoscopy. Histology revealed 
tubulovillous adenoma (n=4), tubular adenoma (n=5), sessile serrated adenoma (n=3) and 
hyperplastic polyps (n=2). Three patients had more than one polyp-type found.  
Stage II patients. 
Nine out of 22 patients in the stage II group had rectal cancer. All were recruited after 
initial staging. Seven patients had neo-adjuvant therapy (six had short course radiotherapy 
and one had long course chemo-radiation), with four then re-classified as stage I based on 
post-operative histology. One patient was found to have stage III based on post-operative 
histology.  
Stage IV patients. 
Thirteen patients had liver metastases of which four had a solitary lesion, two had 
multiple lesions confined to one lobe and seven patients had multiple lesions involving 
both lobes of the liver. Three patients had lung metastases, six patients had distant lymph 
node involvement and two patients had peritoneal involvement. Five patients had more 
than one organ involved. 
Cytokines and patient characteristics  
IL-6 levels were detected in all patients and IL-8 in 59/60 (98.3%) patients whereas TNFα 
was only detectable in 8/60 (13.3%) of patients and IL-1β was detectable in no patients. 




When the Shapiro-Wilk test of normality was applied, none of the distributions of IL-6, IL-
8, CEA or CRP were found to be normal (p<0.001). Therefore, non-parametric statistical 
testing was used to compare each marker by patient characteristic (Table 19). CEA values 
were found to be higher in subjects of non-European ethnicity (median 19.90 µg/L) 
compared with patients of European ethnicity (median 3.00 µg/L) and this was found to 
be statistically significant (p=0.05). CEA values also appeared higher in current smokers, 
patients with high BMI and patients taking regular Aspirin, although these differences 
were not significant. There were no other significant associations between biomarker 














































Cytokines and disease stage. 
When biomarker levels were compared across the three patient groups, IL-6 (p=0.005), IL-
8 (p<0.001), CEA (p<0.001) and CRP (p<0.001) all increased significantly with advancing 
disease stage (Figure 21 and 22).  The increases in IL-6, IL-8, CRP and CEA across stage 
were most pronounced between stage II and stage IV and the widest range of values were 
seen in the stage IV group. 
 






Figure 22. Scatter plots of CRP (A) and CEA (B) values by disease status. *, p<0.05. 
IL-6 varied significantly between control (median 2.46, IQR 1.85-3.98), stage II (median 
2.51 pg/mL, IQR 2.01-3.46 pg/mL) and stage IV (median 6.12 pg/mL, IQR 4.63-10.56 
pg/mL), p=0.005. IL-8 also varied significantly between the three groups: control: median 
3.95 pg/mL, IQR 3.35-6.51 pg/mL; stage II: median 5.59, IQR 4.33-9.27 pg/mL; stage IV: 
median 11.40, IQR 8.39-34.05 pg/mL, p<0.001 (Figure 21). 
CRP increased across the three groups. Control: median 3.00 mg/L (IQR, 3.00-7.00 mg/L); 
Stage II: median 4.00 (IQR, 3.00-9.00); stage IV: median 11.00 (IQR, 7.00-54.00), p<0.001. 





stage II 3.45 µg/L (IQR, 2.00-6.50 µg/L); Stage IV: median 20.50 µg/L (IQR, 4.60-131.20 
µg/L), p<0.001 (Figure 22). 
Given the wide range of values that were observed in the stage IV group, patients in this 
group were further subdivided into those with liver involvement (n=13) to those without 
(n=6). Biomarker levels did not differ significantly between patients with liver involvement 





Figure 23. Scatter plots of IL-6, (A), IL-8 (B), CRP (C) and CEA (D) among stage IV patients, by 







Figure 24. Scatter plots of IL-6, (A), IL-8 (B), CRP (C) and CEA (D) among stage IV patients, by 







The stage IV group was then divided into patients with one organ involvement (n=15) and 
those with more than one organ (n=4). The biomarkers did not differ significantly 
according to these sub-groups: IL-6 (p=0.74), IL-8 (p=0.13), CEA (p=0.41) or CRP (p=0.60) 
(Figure 24). 
ROC curve analysis.  
Receiver operator characteristic curve analyses were performed to evaluate IL-6, IL-8, CRP 
and CEA as discriminators between patient groups.  
CEA was the only individual marker to discriminate between control and stage II disease 
(p=0.008)(Table 20). All four markers discriminated between stage II and stage IV groups, 
the most effective being IL-8 (AUC=0.80) and CEA (AUC=0.81) and all four markers were 
significant discriminators between the control and stage IV groups, again with IL-8 
(AUC=0.90) and CEA (AUC=0.92) the most effective. 
As the two most effective discriminators between patient groups, IL-8 and CEA were then 
combined to produce an IL8-CEA score, ranging from possible scores of zero to two. The 
method by which this combined score was calculated is described in the ‘statistical 
analysis’ section. The ROC curves (Figure 25) demonstrate the IL8-CEA combined score to 
be an effective discriminator between each patient group-pairing, out-performing any one 
marker when compared by area under the curve. The combined score was especially 





Table 20. Receiver Operator Characteristic curve analysis of IL-6, IL-8, CRP, CEA and IL8-CEA by 
disease status comparison.  
 
Control v Stage II Stage II v Stage IV Control V Stage IV 
 
AUC p AUC p AUC p 
IL-6 0.55 0.619 0.75 0.007 0.78 0.003 
IL-8 0.68 0.057 0.8 0.001 0.92 <0.0001 
CRP 0.63 0.163 0.76 0.005 0.83 <0.001 
CEA 0.75 0.008 0.81 <0.001 0.92 <0.0001 
IL8-CEA† 0.77 0.003 0.89 <0.0001 0.99 <0.0001 











































































Figure 26. Scatter plots of IL8-CEA Score by Disease Status 
The median IL8-CEA was 0.42 with an interquartile range of 0.32-0.65. The distribution 
was non-normal upon Shapiro-Wilk testing (p<0.001). The IL8-CEA score increased with 
advancing disease status, from control (median 0.30, IQR 0.26-0.39), stage II (median 0.42, 






In this study of sixty prospectively-enrolled participants, we observed distinct profiles of 
systemic inflammatory markers between healthy controls and colorectal cancer patients 
with stage II and stage IV disease. We found that IL-6, IL-8, CRP and CEA increased across 
the three groups. The widest ranges of values were observed in the stage IV group 
although metastatic site and number of organs involved did not clearly influence any of 
the markers studied. On ROC curve analysis, IL-8 and CEA were identified as the most 
effective discriminators between groups and when combined the resulting score 
outperformed any one marker.  
Our finding that circulating IL-6, IL-8, CRP and CEA increased in association with disease 
progression corroborates other reports298, 303, 395-398. In their study of 75 patients, 
Mahboob et al utilised Proseek and bioplex immunoassays to identify IL-8, CEA and 
Prolactin as the most stage-specific cytokines from their panel of 92 biomarkers 397. 
Olsen’s group measured plasma levels of 40 cytokines in 174 patients and found IL-8, as 
well as CCL20, CCL27 and MIF, to be associated with disease stage 303. Additionally, 
Grotowski et al reported significantly higher levels of serum CEA, IL-6 and IL-8 in patients 
with advanced stage disease compared to those with localised disease 398. Together, these 
findings suggest that systemic pathways involving inflammatory cytokines IL-6 and IL-8 
appear to be activated not only in patients with overt malignant dissemination 382, 399 but 
also in those with macroscopically localised disease, albeit to a lesser degree. It is also 
suggested that serum CEA may be implicated in these pathways398.  
Inflammation within the primary tumour microenvironment is known to involve IL-6216 




immune cells to promote tumour growth and progression193, 211. Furthermore, the link 
between disease stage and systemic inflammation with CEA has been observed 
elsewhere298 and may be explained by mechanisms described by Lee & Lee and 
Beauchemin in their respective reviews 401, 402. Here the evidence is set out in favour of 
tumour-derived-CEA binding with hepatic Kupffer cells, resulting in their production of 
pro-inflammatory cytokines IL-6, IL-1β and TNFα 403, 404. Circulating levels of IL-1β and 
TNFα have been reported to rise in a stage-dependent manner 193 and these two pro-
inflammatory cytokines are known to induce IL-6 and IL-8 via the nuclear factor КB (NF КB) 
pathway 204. The link is further supported by Krystek-Korpacka et al’s finding that CEA 
levels positively correlated with rising IL-6 and IL-8 405. CEA release may therefore provide 
an important link between local and systemic inflammation.  
IL6, IL8, CRP and CEA have been implicated, through experimental evidence, in a number 
of pro-metastatic systemic processes many of which are only beginning to be uncovered. 
In their review article, McAllister and Weinberg 232 summate the experimental evidence 
for tumour-derived factors acting at distant sites to, i) prepare them for  metastatic 
colonisation, ii) promote angiogenesis, and iii) promote the metastatic tumour 
microenvironment. The IL8-CEA combined score developed through the course of this 
study may reflect activity of these pro-metastatic systemic processes and be useful as a 
means of risk-stratifying patients. Although individually IL-8 and CEA have been shown to 
be associated with oncological outcome in colorectal cancer, no other studies have 
evaluated the prognostic value of a combined IL8-CEA score. This requires further 




An association has been observed between inflammatory markers and a number of 
patient characteristics 406. One of the most important of these is advancing age. Franceschi 
et al coined the term, “inflammaging”, which refers to an observed increase in circulating 
levels of inflammatory markers in the elderly population407. Age-related immune 
dysfunction is thought to underlie this as a cumulative result of life-long antigen exposure 
and repeated inflammatory stimuli406. It is noteworthy that other reports 408, 409, including 
the present study, have failed to demonstrate an association between inflammation and 
advancing age. Additionally, our present study did not corroborate others that have 
observed obesity410, ethnicity411 and co-morbidities especially cardiovascular disease412 
and diabetes413, 414, to be associated with circulating levels of inflammatory markers, 
particularly IL-6 and CRP406. Our study may have been underpowered to detect these 
associations, although an association between CEA and patient ethnicity was observed in 
the present study (p=0.05) and has been reported by others415, 416. Therefore, patient 
characteristics may affect circulating levels of CEA and inflammatory cytokines and should 
be evaluated in future longitudinal studies as potential confounders of patient outcomes. 
Limitations 
Selection of Control subjects  
Hospital policy meant that patients undergoing colonoscopy were fasted for a minimum of 
six hours prior to undergoing their procedure. Consequently, circulating biomarker levels 
may have been raised in these subjects due to dehydration and haemo-concentration. 
Additionally, patients recruited into stage II and stage IV groups were not routinely fasted 
prior to having their blood samples taken and this may have introduced measurement bias 




subjects with colorectal malignancy or inflammation to be definitively excluded from the 
group. Furthermore, patients attending hospital investigation under the suspicion of 
colorectal malignancy tended to be similar to patients with stage II and stage IV disease in 
terms of age and co-morbidity (Table 18). A truly healthy control population would have 
significantly varied with regard to these, potentially, confounding variables. 
Additionally, patients with colorectal polyps were included in the healthy control group. In 
their study, Pengjun et al 417 reported differences in the levels of IL-10, IL-8, MMP-2 and 
MMP-9 between patients with adenomas compared to those without and whilst this 
finding was acknowledged, our decision to include patients with polyps was to better 
reflect the general population, in whom colorectal polyps may be present 418-420. 
Furthermore, no patients were included into this group that had a polyposis syndrome or 
evidence of high-grade dysplasia, both of which are associated with an increased risk of 
malignant transformation. 
Sample collection and processing 
A high degree of inter-study variation is observed in circulating cytokine levels and this is 
likely to be due, at least in part, to a non-standardised approach to sample handling and 
cytokine quantification between studies 421-424. Many methodological variables are known 
to influence cytokine levels, including the anticoagulant used, duration of sample storage, 
number of freeze-thaw cycles and manufacturer of assay kits 425, 426. These factors may 
explain the discordant values we observed for IL-1β and TNFα compared to previous 
studies 421-424. However in our study one manufacturer was used to detect all cytokines 




variation 425, 426. Additionally, assay kits with suitable reference ranges were selected for 
use in the study.  
Radiological staging 
The current study was limited by its reliance on radiological staging to define patients with 
stage two rectal cancer. Whilst histopathological staging would provide a definitive 
evaluation, the results would be confounded by response to neo-adjuvant therapies. Our 
approach was more clinic-focussed as staging was assigned based on data available to the 
treating clinical teams at the time of initial treatment decision-making.  
Correlation with local factors 
The extent to which raised circulating inflammatory biomarkers simply reflect 
inflammation within the primary tumour was not addressed in the present study. Galon 
and colleagues have shown that the immunological phenotype within the primary tumour 
has an important bearing on outcome, as demonstrated by their validated 
“immunoscore”162, 163, 186. Furthermore, an association between tissue IL-6 concentration 
and advancing TNM stage has been shown although has not been widely studied427. 
Finally, Vӓyrynen et al attempted to evaluate the relationship between the immune cell 
density within the primary tumour and circulating inflammatory markers to suggest an 
association, although weak, may exist 180, 306. The markers measured in the present study 
are not tissue-specific and the primary tumour, as well as the liver and pre-metastatic or 
metastatic sites may have contributed to the circulating concentrations measured. On the 
other hand this may be an advantage in providing global evaluation of the host-response 





The results of this study suggest a systemic inflammatory disturbance may occur in 
colorectal cancer patients prior to overt disseminated disease. Whilst widely studied 
prognostic tools including the modified Glasgow prognostic score and neutrophil-
lymphocyte ratio incorporate this principle, they rely on non–specific markers of 
inflammation. In the context of emerging evidence of both pro- and anti-tumour systemic 
inflammatory pathways, more specific markers or combinations of markers are needed to 
develop prognostic tools that are applicable in the clinical setting. Furthermore, we found 
that a combined score of IL-8 with CEA acted as an effective marker for systemic disease. 













Exploratory prospective study of 





In Chapter Four, we found individual cytokines IL-6 and IL-8 to differ significantly between 
patients with localised and systemic disease. Furthermore, it has been put forward that a 
proportion of early recurrences in colorectal cancer are due to systemic micro-metastases 
present at the time of initial treatment428. Therefore, cytokine markers including IL-6 and 
IL-8 may be useful in predicting early recurrence by identifying patients with otherwise 
occult distant metastases.  
We also found that combining IL-8 with CEA resulted in an improved sensitivity and 
specificity in identifying patients by disease status, compared to either marker alone. It is 
pertinent to also examine this combination in a prospective prognostic study. As CEA is 
the most widely studied circulating prognostic biomarker in colorectal cancer and one of 
the few if not only to be measured in everyday clinical practice, its prognostic value would 
provide a useful benchmark against which to compare more novel approaches.  
Although a paucity of data was available in the literature, a multi-marker approach was 
found to show some prognostic value, based on the findings of our systematic review 
(Chapter Three). This is not surprising given the multi-faceted interaction between the 
tumour and host through a multitude of inflammatory pathways including both pro- and 
anti-tumour activity. In Chapter Three, we identified a shortfall of the included studies to 
be the study of very large panels of cytokines that were not justified through experimental 
or clinical evidence linking them to colorectal cancer progression or prognosis. Given the 
wide range of inflammatory cytokines, we selected a panel of eight cytokines with roles in 
colorectal cancer progression that have been observed experimentally. These cytokines, 




Table 21 Experimental data linking cytokines with colorectal cancer progression 
Cytokine Mechanisms of Action in Colorectal Cancer Progression Reference 
TNFα   
 Activates NF-kB in intestinal epithelial cells to promote proliferation and 
resistance to apoptosis 
429 
 Induces EMT in CRC through activation of SNAI1 430 
 Triggers proliferation of CRC cell lines in a STAT3-dependent manner 390, 431 
 TNF blockade diminishes tumour development in AOM-DSS-treated mice 432 
IFN-ϒ   
 Ifng-/- mice show more and larger intestinal tumours compared to wild-type 433 
 Stimulates anti-tumour immunity through CD8+ T-, NK cell- and macrophage-
mediated cytotoxicity 
434 
 Exogeneous IFN-g inhibits growth of HT-29 CRC cells in mice . Inhibits 
EGFR/Erk1/2 and Wnt/B-catenin signaling pathways through induction of 
STAT1 
435 
IL-2   
 Anti-tumour effects through activation of NK cells 436 
 Systemic IL-2 therapy decreased tumour burden in mice with colonic 
adenocarcinoma (CC-36 cell line) 
437 
IL-4   
 Promotes EMT of CRC cells through activation of STAT6 and loss of e-cadherin 438 
 Activates M2-like TAM polarization in CRC 439 
IL-6   
 IL6-dependent STAT3  signaling promotes CRC cell line DSS-AOM proliferation 
and survival 
386, 440 
 Pro-tumourigenic effects observed through induction of Notch1 and CD44 
expression 
441 
 Induction of microsatellite instability in CRC cell lines 442 
 NF-KB-IL6-STAT3 pathways promotes CRC progression 443, 444 
 Induces EMT via JAK2/STAT pathway 445, 446 
IL-8   
 Promotes outgrowth, vascularity and metastasis of CRC xenografts 207 
 Induces tumourigenesis and tumour angiogenesis in DSS-AOM mouse CRC 
model 
388 
 Promotes cell proliferation, invasion and angiogenesis through activation of 
Akt and MAPK pathways 
206 
 Promotes EMT in CRC cell lines 210, 447 
 Addition to CRC cells suppresses apoptosis 448 
IL-10   
 Required in Treg cells to reduce tumour burden in ApcMin/+ mice 449 
 IL-10 deficient mice more susceptible to intestinal tumour development 450 
IL-17A   
 Deficiency partially protects mice from CRC in ApcMin/+ and AOM-DSS models 451, 452 
 Promotes secretion of VEGF, inducing tumour angiogenesis 453 
 Facilitates cell cycle progression in CRC cell lines through increased expression 
of Sca-1 
454 






The aims of this chapter were: 
❖ To evaluate baseline plasma IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, IFNϒ and TNFα as 
predictors of disease free survival in a cohort of patients undergoing treatment of 
colorectal cancer with curative intent 
❖ To compare the above cytokines with clinico-pathological factors as predictors of 
disease free survival. 




This was a single-centre prospective observational cohort study.  
Patient selection & recruitment  
Consecutive patients with newly diagnosed stage I to III colorectal adenocarcinoma 
undergoing treatment with curative intent at Wellington Regional Hospital between 
October 2016 and June 2018 were eligible for recruitment in this study.  
The exclusion criteria, ethics and plasma sample collection and storage were as described 
in Chapter Four (4.2). All of the stage II patients from the Chapter Four study were also 





Clinical, radiological and histopathological data were collected prospectively for the 
cohort. This included demographic variables (age, sex, ethnicity, past medical history, drug 
history), and tumour characteristics (location, AJCC stage, perineural invasion, 
lymhpovascular invasion, cell type, histological grade). Microsatellite instability (MSI) 
status was based upon histological evidence of deficient mismatch repair proteins MLH1, 
MLH2 or MSH. Data on the treatment received was also collected (neo-adjuvant therapy, 
adjuvant therapy).  
Sample collection & Storage 
Sample collection and storage was as described in Chapter Four (5.2).  
Cytokine measurement. 
Assays were performed using cytometric bead array (BD Biosciences) and were not carried 
out by the author.  All assays, however, were carried out by or under the direct 
supervision of experienced University research staff. 
Cytometric Bead Arrays (CBA) 
A FACSCantoTM II plate loader-equipped flow cytometer (Becton Dickinson, USA) was used 
with BD FACSCompTM software and BD CaliBRITETM beads (BD, Biosciences) for data 
acquisition and FCAP ArrayTM software was used for data analysis.  
BDTM CBA Flex Sets (BD Biosciences) were used for IL-2 (Catalogue #558270) and TNFα 
(Catalogue #558273) with Human soluble protein master buffer kits (Catalogue #558265) 
(BD Biosciences). BDTM CBA enhanced sensitivity flex sets were used for IFN-ϒ (Catalogue 
#561515), IL-6 (Catalogue #561512), IL-8 (Catalogue #561513), IL-10 (Catalogue #561514), 




sensitivity master buffer kits (Catalogue #516523) (BD Biosciences). All assays were 
optimised so that each analyte had 300 bead events captured and were performed 
according to the manufacturer’s instructions.  
Clinical follow up & Endpoints  
Patients were followed up according to a standard protocol that was implemented by the 
Department of General Surgery at Wellington Regional Hospital in line with the New 
Zealand Guidelines Group document ‘management of early colorectal cancer’ 12. This 
included three to six monthly outpatient clinic assessments, yearly CT chest, abdomen and 
pelvis scans and three-monthly serum carcinoembryonic antigen measurement. Endpoint 
data was collected prospectively following the censor date of 1st July 2019 in order to 
allow a minimum of 12 months follow-up for the cohort.  
The endpoint measured was Disease Free Survival, defined as the time from surgery to 
either recurrence (local or distant) or death. Recurrence was by histological confirmation 
or following radiological assessment and multi-disciplinary team consensus opinion.  
Statistical analysis 
In addition to the statistical methods described in the Chapter Three, Receiver operator 
characteristic curves were used to identify the optimal cut-off value for individual 
cytokines. A cut off value of 3.0ng/mL was used for pre-operative CEA, based on the 
findings of Chapter Two. Kaplan-Meier curve analysis was performed using the Mantel-Cox 
log rank test in order to compare disease free survival by clinical-pathological variable and 






All patients were recruited and samples collected and stored with ethical approval by 
Health and Disability Ethics Committee (‘Establishment of human tissue bank of surgical 
cancers for future unspecified research, ref: 15/CEN/143). Cytokine measurement was 
approved by the Health and Disability Ethics Committee (‘Molecular biomarkers in 
colorectal cancer’, ref: 18/CEN/138). The Ngai Tahu Research Consultation Committee 






174 patients were eligible for recruitment of which 101 patients were excluded leaving 73 
patients included in the study. The reasons for exclusion are illustrated in Figure 27.  
 





The patient demographics are shown in Table 22. The median age was 70 years, 49.3% 
were male and 87.7% of European ethnicity. Aspirin was taken by 17.8% of patients and 
another form of Non-steroidal anti-inflammatory drug (NSAID) was taken by a further 
5.5%.  














Patient characteristic N   (%) 
Age, years 
  Median (IQR) 
 
70     (60-77) 
Sex 
  Male 
  Female 
 
36     (49.3) 
37     (50.7) 
Ethnicity 
  European 
  Other 
 
64     (87.7) 
9       (12.3) 
BMI, kg/m2  Mean (SD) 27.8 (5.5) 
Smoker 6       (8.2) 
PMHx 
  IHD 
  DM2 
 
9       (12.3) 
11     (15.1) 
  CVD 2       (2.7) 
  Renal 2       (2.7) 
  Liver 2       (2.7) 
DHx 
  Aspirin 
  Other NSAID 
 
13     (17.8) 
4       (5.5) 
  Insulin 2       (2.7) 
  Metformin 5       (6.8) 
PMHx: Past medical history, IHD: ischaemic heart disease, 
DM2: diabetes mellitus type 2, CVD: cerebro-vascular disease; 






The cohort included 46 colonic cancers and 27 rectal cancers. According to TNM staging, 
there were 11 stage I, 30 stage II and 32 stage III patients (Table 23). Tumour 
characteristics by cytokine (Table A1) and associations between cytokines (Table A2) are 
shown in the Appendix. 


















Tumour Characteristic N (%) 
  
Site 
  Right colon 
  Left colon 






   I 
   II 






  High 




Mucinous   
  Yes 
  No 
8   (11.0) 
65 (89.0) 
Perineural invasion 
  Yes 





  Yes 
  No 
 
9   (12.5) 
63 (87.5) 
Lymph node yield ≥12 
  Yes 





  Yes 








Neo-adjuvant therapy was administered in 17/27 (63.0%) of patients with rectal cancer. 
Ten out of 27 (37.0%) received short course radiotherapy and seven of 27 (25.9%) 
received long course chemo-radiation. 
Adjuvant chemotherapy was recommended at multidisciplinary meeting in none of 11 
patients with stage 1 disease, nine of 30 (30.0%) with stage II and 22 of 32 (68.8%) with 
stage III. Four out of nine (44.4%) stage II patients in whom adjuvant chemotherapy was 
recommended went on to complete treatment compared to 16/22 (72.7%) in stage III. 
Five patients declined chemotherapy, four patients developed toxic side effects and two 
developed a medical complication requiring early termination of treatment (one deep vein 
thrombosis and one myocardial infarction). Eight patients were not offered chemotherapy 
following clinic assessment by a medical oncologist.  
Outcomes 
The median duration of follow-up was 18 months with a range of 12-31 months. During 
this time there was one death (1.4%), which was cancer-related and occurred at 10 
months in a patient who developed distant metastatic disease. 
There were seven (9.58%) recurrences in total, including one local recurrence. The local 
recurrence was detected at the site of anastomosis at 20 months follow up in a patient 
who did not develop distant recurrence.  
There were six (8.2%) distant recurrences detected at a median of 13 months, ranging 
from one to 22 months, of follow up. The liver and the peritoneum were the most 




more than one site involved, both of which were distant in each case. None of the patients 
had lung metastases. 
Plasma Cytokines 
Three out of the ten cytokines (IL-6, IL-8 and IL-10) resulted in detectable readings in at 
least 75% of the cohort (Table 24). The remaining cytokines were therefore excluded from 
further analysis. The lower limit of detection of the assay was used as the cytokine value in 
cases where levels fell beneath this. 
 
Table 24. Number of patients with detectable levels and limits of detection, by cytokine assay 
Cytokine Detectable 
Levels, N 73 (%) 
Limit of 
Detection, fg/mL 
IL8 71  (97.3) 69.9 
IL6 60  (82.2) 68.4 
IL10 60  (82.2) 13.7 
IL17A 30  (41.1) 26.1 
TNFα 6    (8.2) 0.7 
IL2 2    (2.7) 88.9 
IL4 1    (1.3) 140 
IFNϒ 0    (0) 14.8 
IL: Interleukin, TNF: Tumour necrosis factor; IFN: 
Interferon 
IL-6 
The median IL-6 value was 2118.09 fg/mL (IQR, 318.52-3359.78). Using the Shapiro-Wilk 
test, the data was found not to be normally distributed (p<0.001). The skewness Z-score 





The median IL-8 value was 7020.23 fg/mL (IQR, 4074.46-10718.38). Using the Shapiro-Wilk 
test, the data was found not to be normally distributed (p<0.001). The Skewness z-score 
was 9.4 and Kurtosis Z-score 8.0. 
IL-10 
The median IL-10 value was 423.56 fg/mL (IQR, 76.42-778.65). Using the Shapiro-Wilk test, 
the data was found not to be normally distributed (p<0.001). The Skewness z-score was 
16.3 and Kurtosis Z-score 46.2. 
Receiver Operator Curve Analysis  
On Receiver Operator Characteristic (ROC) curve analysis, IL-10 (AUC=0.66) was associated 
with the highest areas under the curve, although the AUCs were similar for all three 
individual cytokines (Table 25). An optimum cut-off value was selected for each of the 
markers and are presented in the table below along with their corresponding sensitivity 






Table 25. Receiver operator characteristic curve analysis for disease free survival, by circulating 
biomarker 
 IL-6, fg/mL IL-8, fg/mL IL-10, fg/mL 
AUC 0.65 0.63 0.66 
Cut off value 2646.85 7112.04 151.59 
Sensitivity, % 71.4 71.1 65.2 
Specificity, % 65.2 54.5 85.7 




























































After cut-off points were determined using the above method, a high IL-6 was found to be 
associated with high histological grade (p=0.02) and microsatellite instability (p=0.01). IL-6 
was strongly associated with IL-8 (p<0.001) but not IL-10 (p=0.58) (Appendix – Table A1. IL-
10 was not associated with IL-6 (0.58) or IL-8 (p=0.60) (Appendix – Table A3). 
 
Survival Analysis 
Kaplan-Meier curve analyses were performed to evaluate the ability of each prognostic 
marker to predict disease free survival.   
 
Figure 29. Kaplan-Meier curves of disease free survival by TNM stage 
Although a trend toward decreasing DFS was observed with advancing stage, this was not 
found to be statistically significant (p=0.28) (Figure 29). However, mucinous (p=0.01), high-
grade histology (p=0.04) and MSI (p=0.002) were significantly associated with a poorer 




Out of the three individual cytokines, only IL-10 (p=0.01) was associated with DFS, where a 
low IL-10 predicted poor DFS. IL-6 (p=0.06) and IL-8 (p=0.13) were not associated with DFS 
(Table 26, Figure 30). 
IL8-CEA Score 
Given that IL8-CEA was found to be an effective discriminator by disease status in Chapter 
Five, we evaluated its prognostic value in the present study. Patients with a both a raised 
IL8 and CEA were given a score of ‘1’ and all others were scored ‘0’. This method was 
chosen in order to produce a dichotomous variable for simplicity and ease of subsequent 
analysis. Equal weighting was given to both variables due to a lack of data in the available 
literature comparing the effect size of IL8 and CEA in predicting DFS.   
Disease Free Survival was 73.7% in those with an IL8-CEA score of ‘1’ compared to 96.3% 
in those with a score of ‘0’ (p=0.003) (Figure 30).  
IL10-CEA Score 
IL-10 was identified as the individual cytokine with the greatest ability to stratify patients 
into favourable and poor DFS in sample population. Therefore, it was combined with CEA 
in order to produce evaluate a combined IL10-CEA score. Given the inverse relationship 
between a high IL-10 and poor DFS, a combined score of ‘1’ was assigned for patients with 
both a low IL-10 and high CEA. All others were assigned a score of ‘0’.  
Disease Free Survival was 68.5% in those with an IL10-CEA score ‘1’, compared to 96.5% in 
those with a score of ‘0’ (p=0.001). This showed some improvement on CEA alone, which 
was associated with a DFS of 83.8% when raised and 97.2% when not raised (p=0.03) 




Table 26 Disease Free Survival by Tumour Characteristic and Circulating Biomarker 
 DFS (%) P Value 










































































































































This exploratory study of 73 prospectively recruited patients, found low IL-10 to be an 
indicator of poorer disease free survival in stage I-III colorectal cancer after a median 
follow-up duration of 18 months. We found that combining this cytokine marker with CEA 
appeared to improve upon the prognostic value of CEA alone.  
Our observation of an inverse relationship between high IL-10 and distant recurrence has 
been reported, although not consistently, in the published literature 291, 455, 456. A meta-
analysis by Zhao et al included 1788 patients from 21 studies and concluded that a raised 
baseline IL-10 was associated with poorer overall and disease-free survival455 across 
numerous cancer types. However, only 30 patients with colorectal cancer were included in 
this meta-analysis and it is uncertain whether the authors’ conclusions can be generalised 
to this cancer type 291. Abtahi et al observed a “dual association” of serum IL-10 and 
colorectal cancer whereby IL-10 levels were lower in CRC patients than in controls but 
higher in CRC patients with poor prognosis 456. The validity of their study is similarly 
limited by its small sample size of 30 subjects but whose findings nevertheless reflect 
experimental data on the role of IL-10 in CRC, which is similarly opposing. That is to say, 
evidence exists both of a protective role of IL-10 by inhibiting cancer-enabling 
inflammation as well as a tumourigenic role through inhibition of anti-tumour 
immunity456. Huang et al’s in vivo study on human melanoma cell line A375P in mice 
demonstrated anti-tumour and anti-metastatic activity of IL-10 457. Such properties were 
demonstrated by Birgisson et al who, in their study of 261 colorectal cancer patients, 
found recurrence free survival to be shorter in patients with low IL-10458. These results 




statistically significant on Cox regression univariate analysis (p=0.07). The potentially “dual 
role” of IL-10 in colorectal cancer highlights the importance of interpreting IL-10 levels in 
combination with other markers.   
In Chapter Four, we found that an IL8-CEA score was associated with the presence of 
metastatic disease. In addition to this, the IL8-CEA, and IL10-CEA, scores in the present 
study showed some association with DFS on Kaplan-Meier curve analysis. The combined 
score may act as a marker for occult metastases present at the time of surgery, or 
alternatively, indicate pre-metastatic niche formation. In their CRC mouse model, Seubert 
and colleagues showed that pre-metastatic niche formation within the liver was in part 
dependent on neutrophil chemotaxis 459 , which in turn is known to be a main function of 
IL-8 388. Additionally, Shao et al demonstrated the release of IL-6 from Kupffer cells upon 
the arrival of exosomes derived from primary CRC cells prior to their dissemination460. 
However, the short follow-up duration in the present study make pre-metastatic niche 
formation a less likely mechanism of the recurrences observed than occult metastases 
that were already present.  
We observed a poorer DFS in patients with both a raised IL-8 and CEA, compared to a 
raised CEA alone. This observation may indicate a functional role for the CEA molecule in 
systemic inflammatory pathways. Such a role has been demonstrated experimentally by 
Holmer and colleagues in their in vitro study whereby colon cell lines incubated with IL-6 
were found to upregulate expression of CEA-related cell adhesion molecules CEACAM5 
and CEACAM6 461. Furthermore, Wagner et al found that human colon cancer cell lines 
expressing high levels of CEA were much more likely to metastasise to the liver of mice 




activation of Kupffer cells by CEA-binding to be accompanied by inflammatory cytokine 
release, including IL-6464. A further advantage of utilising a combined Cytokine-CEA score is 
to offset the paradox that poorly differentiated colorectal cancers, whilst known to be 
associated with poorer prognosis465, are less likely to have preserved CEA expression343.  
Limitations 
The current study has a number of limitations to acknowledge.  
Primarily, the sample size and particularly the number of events, seven, meant that this 
study was significantly underpowered. This is apparent by the unexpected finding that 
TNM stage was not predictive of DFS although a trend toward worsening DFS by advancing 
stage was observed, particularly in stage III patients compared to stage I and II. Given the 
low number of events it is possible that by dividing the cohort into three groups by TNM 
stage diminished the statistical power, beyond other analyses of dichotomous variables. 
As the prognostic value of TNM stage in predicting DFS is well-established, this finding 
calls into question the validity of the other findings of this study. 
Furthermore, a general rule-of-thumb for regression analysis is the “rule of ten”. That is, 
one predictive variable should be studied per every ten events in order to minimise 
overfitting 466. As a minimum for this, two variables, TNM stage and a single circulating 
biomarker, would be included as independent variables in a multi-variate regression 
analysis, requiring approximately twenty events. In Chapter Two, we found a recurrence 
rate of 53/227 (23.3%) in stage I to III patients over five years of follow-up. Therefore, 
between 80 and 90 patients would have had to be recruited and followed up for five 




emergency presentations, which are associated with poorer outcomes. The inclusion of 
other prognostic variables such as histological grade, lymphovascular and perineural 
invasion and MSI status in multi-variate regression analysis would further increase the 
number of required events. However, achieving such a sample size and follow-up duration 
was not feasible given the time- and resource-constraints of the present study. As part of 
this exploratory study, Kaplan-Meier curves were utilised to compare DFS by a single 
variable at a time. However, this meant that the association between a circulating 
biomarker and DFS was not adjusted for any of the other established predictors of DFS, 
including TNM stage and thus vulnerable to confounding. 
Further to this, the study sample was heterogeneous in terms of a number of important 
factors including tumour location (colonic and rectal), nodal involvement and the 
administration of neo-adjuvant and adjuvant therapies. As a result, aspects of tumour 
biology such as responsiveness to systemic therapies may have further confounded the 
results of this study. In order to address this, sub-group analysis would be necessary.  
Baseline CEA results were visible to treating clinicians during this study and may have 
introduced bias. The pre-operative CEA could have influenced the multi-disciplinary 
team’s decision to diagnose metastatic disease on staging imaging, or recurrence on 
surveillance imaging. Blinding the clinical teams to pre-operative CEA values would not be 
feasible or ethical given that it makes up part of the standard of care. Additionally, 
patients with a raised pre-operative may have been followed up more closely although 
data from the present study in insufficient to confirm or refute this. Additional study into 
the compliance with surveillance investigations and follow-up was outside the scope of 




A possible anomaly of the present study is the finding that none of the recurrences 
observed in the present study occurred in the lungs. This is in contrast to our findings in 
Chapter Two, where the lung was found to be the second most common site of metastasis 
after the liver. In their population-based study of 5671 colorectal cancer patients 
undergoing treatment with curative intent, van Gestel et al found 20% of lung metastases 
to occur within one year, compared to 40% of liver metastases465. The longer time-to-
recurrence reported with lung metastases may have meant that with a relatively short 
follow-up duration in the present study lung metastatic recurrences were effectively 
selected out.    
An additional limitation to this study is the equal weighting given to the components of 
the combined (IL8-CEA and IL10-CEA) scores, despite it being unlikely that their effect size 
on DFS is exactly equal. This could be addressed in a larger, sufficiently powered, study by 
performing Cox proportional regression. The hazard ratio could be calculated for IL8, IL10 
and for CEA based on univariate Cox regression, as predictors of DFS, and taken to be the 
effect size of each marker. IL8, IL10 and CEA could then be appropriately weighted 
according to their respective effect sizes to produce the combined score. This score would 







In this exploratory prospective study, we found IL-10 and CEA to be indicators of disease 
free survival among 73 patients with stage I-III colorectal cancer undergoing treatment 
with curative intent, after a median follow up duration of 18 months.  
Combined IL8-CEA and IL10-CEA scores appeared to improve upon CEA alone in predicting 
disease free survival. Although the study was underpowered, as a proof-of-concept, it 
suggests there may be an added benefit to combining circulating inflammatory cytokine 
measurement with baseline CEA to prognosticate patients with colorectal cancer. This is a 
novel approach and requires further investigation to test this hypothesis using multi-
variate regression and sub-group analysis in a large prospective longitudinal study with 


























Colorectal cancer is a major cause of cancer-related mortality and, despite recent 
advances in treatment, the five-year recurrence rate following surgery is around 20%323, 
335. The ability to stratify patients according to risk of recurrence is critical in guiding 
therapeutic management decisions and historically has relied on the TNM stage and other 
tumour characteristics. However, the host-response is becoming increasingly recognised 
as playing an influential role on clinical outcomes. In turn, circulating biomarkers may offer 
a means by which tumour-host interactions are evaluated.  
The aims of this thesis stem from a growing body of evidence linking systemic 
inflammation to disease outcome through a number of proposed mechanisms and these 
are described in Chapter One. Ultimately, we set out to investigate whether circulating 
inflammatory cytokines provide prognostic value in potentially curable colorectal cancer. 
Chapter Two includes a retrospective cohort study including patients undergoing 
treatment with curative intent at a single institution between 2010 and 2012. We 
evaluated the pattern of disease recurrence in 237 consecutive patients, of whom 24.9% 
developed recurrence at a median follow up of 61 months. We found that distant 
recurrences made up the majority (74.6%) of those observed and that 72.9% of all 
recurrences were observed in the first two years of follow-up with annual recurrence rates 
diminishing significantly thereafter. Such early distant metastases may represent a sub-set 
of patients in whom occult systemic disease is present at the time of surgery. In turn, 
circulating biomarkers may provide a means of identifying patients with otherwise occult 
disease. Next, we evaluated the prognostic value of pre-operative carcinoembryonic 




clinical practice, we found only 58.6% of patients to have data available for baseline CEA; 
the remaining patients were therefore excluded. We found that with an optimum cut-off 
value of 3.0ng/mL, CEA had a sensitivity of 70% and a specificity of 52% in predicting 
disease free survival. In contrast to a number of existing studies, which use 5.0ng/mL as 
the cut-off, this finding suggests there may be prognostic value from a high-normal pre-
operative CEA 351.  On multi-variate analysis, pre-treatment CEA was found to be an 
independent predictor of disease free survival (HR 1.99, 95% CI 1.07-3.69, p=0.03) and 
overall survival (HR 3.17, 95% CI 1.46-6.89, p=0.004). On the basis of these findings, CEA 
was established as a benchmark against which other, more novel, circulating biomarkers 
could be compared in future studies. The practices and outcomes we observed in Chapter 
Two were comparable to those of other contemporary cohorts in the published literature. 
This meant future studies at the same institution, as part of this thesis, were unlikely to be 
subject to biases from anomalous clinical practices or outcomes.  
In Chapter Three, we turned to circulating inflammatory cytokines. Through experimental 
evidence, a number of cytokines have been implicated in pro-metastatic systemic 
pathways232. Studies have shown circulating levels of individual cytokines IL-6, TNFα and 
IL-1β among others to be prognostic but few have undertaken a multi-marker approach 
216, 376, 398, 467. Chapter Three was a systematic review of the literature evaluating the 
prognostic value of multiple cytokine analysis in colorectal cancer. Seven studies were 
included in the review, which excluded studies evaluating two or fewer cytokines. Five 
studies included patients with stage I-IV disease; the remaining two studies included stage 
IV disease only. Only two studies were prospective in design and three of the seven 




generally small, ranging from 46 to 205 and we found study quality to be poor to 
moderate, based on the risk of bias across six domains. Additionally, there was a high 
degree of variability in the size and contents of the cytokine panels tested. Four studies 
tested panels of ten or greater cytokines using pre-manufactured panels and failed to cite 
evidence justifying many of the cytokines tested. Four studies utilised a combined 
cytokine score and some promise was shown of this approach, although variation existed 
in the cytokines included and criteria used to create the score. The results of the 
systematic review did not yield a panel of candidate cytokine markers for further study 
partly due to the high number and wide range of cytokines studied. However, the review 
did inform our approach of selecting a small panel of cytokines justified through 
experimental data of a link with colorectal cancer progression.  
In Chapter Four, participants were prospectively recruited into three groups. Plasma 
cytokines IL-6, IL-8, IL-1β and TNFα were compared across the groups: healthy control 
subjects (n=19), stage II (n=22) and stage IV (n=19). For a biomarker to be prognostic, we 
would expect it to differ between these three disease states. Based on the findings of 
Chapter Two, pre-treatment CEA was included in the study for comparison. TNFα and IL-
1β levels were detectable in fewer than 75% of the cohort and were therefore excluded 
from further analysis. We found IL-6 (p=0.005), IL-8 (p<0.001) and CEA (p<0.001) to 
increase significantly with advancing disease status and a combined ‘IL8-CEA score’ was 
marginally more stage-specific than either marker alone (p<0.0001). IL-6, IL-8 and CEA 
were among those studied further in Chapter Five. This was an exploratory study of a 
panel of cytokines for evaluation as prognostic markers, by means of a longitudinal 




Here, 73 patients with newly diagnosed non-metastatic colorectal cancer were 
prospectively recruited at a single institution. Baseline plasma samples were collected and 
subsequently analysed by CBA for a panel of eight cytokines. This panel was selected on 
the basis of experimental evidence linking each cytokine to CRC progression. This included 
IL-6 and IL-8 from the previous study in addition to TNFα, IFNϒ, IL-2, IL-4, IL-10 and IL-17A. 
Among the eight cytokines tested, IL-6, IL-8 and IL-10 yielded recordable values in greater 
than 75% of the cohort and the remaining five cytokines were excluded from further 
analysis. Patients were followed up to a minimum of 12 months post-operatively. The 
median follow up duration was 18 months (range, 12-31 months) and the disease free 
survival was 90.4%. Individually, CEA (p=003) and IL-10 (p=0.01) were found to be 
predictive of disease free survival on Kaplan-Meier survival curve analysis. Following the 
findings of Chapter Four, whereby the combining of IL-8 and CEA improved upon CEA 
alone in differentiating disease status, we evaluated a combined IL8-CEA score in this 
study as well as IL10-CEA, given that IL-10 was identified as a potential prognostic marker 
through Kaplan-Meier curve analysis. We found that both scores appeared to improve 
marginally upon CEA alone in identifying a sub-set of patients with poorer disease free 
survival. However, the study sample size and follow up duration precluded any multi-
variate survival analysis or sub-group analysis. Therefore, it was not possible to conclude 
whether a raised IL8-CEA or IL10-CEA score is an independent prognostic factor for poor 
prognosis in colorectal cancer. Instead, the results identify IL-8 and IL-10 as potential 
candidates for future evaluation through longitudinal prognostic studies, and suggest a 






There were a number of overall limitations of the studies included in this thesis to 
acknowledge.  
Firstly, the clinical studies were all carried out at a single clinical institution. This may in 
turn impact the generalisability of our findings to other centres and patient populations. In 
order to address this problem, we explored the option of extending patient recruitment to 
a second hospital. As well as broadening patient participation this would have also 
increased the sample size and with it statistical power. However, due to distance from the 
University laboratory, there would have been an unacceptable delay to processing. 
Specifically, our target of centrifuging all blood samples within thirty minutes would not 
have been possible and consequently the decision was made to confine recruitment to the 
host institution so not to compromise the quality of stored plasma samples. In addition to 
these resource-constraints, the time-constraints of this thesis ultimately prevented our 
ability to perform a comprehensive prognostic longitudinal study. The study described in 
Chapter Five was significantly underpowered for such an analysis, which would require a 
five-year follow-up duration and a much larger sample size. These measures would 
improve the statistical power, and allow a multi-variate Cox proportional hazard model to 
be utilised. This study design would also allow for other prognostic factors such as TNM 
stage, histological grade, lymphovascular and perineural invasion to be adjusted for.  
The problem of over-fitting is relevant to the studies included in this work whereby an 
optimal cut-off value was determined for a variable in the same data set that it was 
evaluated in. Examples of this include the pre-operative CEA in Chapter Two, and 




may have over-estimated the true effect of the measured variable on outcome. A measure 
in which to address this would be to externally validate these same cut-off points in an 
independent study sample.  
Although the TNM stage is widely acknowledged as the most reliable and strongest 
predictor of prognosis in colorectal cancer, it was not identified as an independent 
prognostic predictor in Chapter Two, when only patients with available CEA data were 
analysed. Although the sample size and therefore the statistical power was significantly 
reduced in the second part of the study by excluding patients with missing CEA data, one 
would still expect TNM stage to be a stronger prognostic predictor than pre-operative 
CEA, as has been found elsewhere in the literature. Similarly, TNM stage failed to be 
observed as a significant predictor of DFS on Kaplan-Meier survival curve analysis in 
Chapter Five. It is possible that the findings were confounded by the stage-dependency of 
treatment regimes, such as the greater likelihood of patients with Stage III to receive 
adjuvant chemotherapy, compared with Stage II disease. Nevertheless, the results are 
discordant with the existing available literature and this must be considered when drawing 
other conclusions from the study. 
It must be noted that the conclusions of this thesis regarding the prognostic role of 
inflammatory cytokines cannot be generalised to emergency presentations. This applies to 
up to 20% of all CRC presentations 46. Emergency patients, especially those presenting 
with perforation, are likely to exhibit grossly deranged inflammatory cytokine levels as a 
consequence of their pathology. In contrast, changes in the baseline inflammatory state 




comparatively subtle. Therefore, emergency presentations were excluded to prevent 
skewed data and an impaired ability to assess the host-response to cancer.  
An improvement to the present study would be the post-operative measurement of CEA 
and cytokine values. There is evidence that post-operative biomarker levels may be more 
prognostic than pre-operative values. For example, Konishi et al observed a similar 
prognosis in patients with a normal pre-treatment CEA to those with a raised pre-
treatment CEA that normalised after surgery129. The difficulty with applying the same 
approach and measuring post-operative plasma cytokine levels is in selecting an 
appropriate post-operative time-point. A number of factors in the peri-operative 
timeframe could influence plasma cytokine levels including the operative approach, 
duration of surgery and the incidence of post-operative complications especially infective 
or inflammatory complications, such as anastomotic leak. Whether post-operative 
samples should be taken before or after adjuvant therapy would also have an impact on 
the results, particularly in the presence of toxic side effects such as colitis.   
6.2 Future Directions 
The findings of this thesis suggest that circulating inflammatory cytokines may provide 
additional prognostic value to CEA alone. The next step would be for the IL10-CEA score, 
developed through this body of work, to be externally validated in a large prospective 
cohort study. This requires a significantly larger sample size and a follow up duration of 
five years to provide sufficient statistical power. Furthermore, multivariate analysis or sub-
group analysis would be necessary to account for confounding variables, including TNM 
stage. Additionally, it is important to investigate the association between systemic 




administered. Such studies would include stage 1 and low-risk stage II patients only and 
therefore require significantly larger sample sizes due to the lower distant recurrence rate 
than those observed in our studies.  Were a combined IL10-CEA score to be externally 
validated as a predictor of DFS, particularly in patients who would not ordinarily be 
offered adjuvant chemotherapy, there could be scope for further study into the benefit of 
adjuvant chemotherapy in such individuals.  
The link between systemic inflammation and outcome in colorectal cancer has led to 
interest into the therapeutic benefits of anti-inflammatory agents. Although the 
mechanism remains unclear, a number of retrospective observational studies have 
suggested Aspirin use to be associated with reduced CRC mortality468. Furthermore, there 
is some indication that COX-2469 and PIK3CA470 may act as predictive biomarkers of a 
survival benefit of adjuvant Aspirin use. The findings of our thesis further strengthen the 
link between systemic inflammation and prognosis in colorectal cancer and future work 
should be carried out in the form of large prospective studies to investigate the potentially 
beneficial role of adjuvant Aspirin or NSAIDs in CRC. 
Monoclonal antibodies that target specific cytokines have also been investigated in the 
treatment of solid tumours with some benefit 471, 472. For instance, Siltuximab, an anti-IL6 
agent, was shown in a phase I/II clinical trial to stabilise disease in more than 50% of 
patients with progressive metastatic renal cell cancer473.  Currently, no clinical benefit has 
been seen from Siltuximab in patients with advanced colorectal cancer474 although the 
evidence is limited to a single phase I/II trial. Some have suggested that targeting a single 
cytokine is unlikely to be beneficial when multiple cytokines are known to act as part of a 




cytokines have been shown to influence outcome. Combination therapies with multiple 
cytokine targets have been proposed and based on our findings, IL-8 is an additional 
potential target. A phase I trial of HuMax-IL8, an anti-IL8 monoclonal antibody, has shown 
the drug to be safe and well-tolerated in fifteen patients with solid organ tumours, 
including four patients with colorectal cancer475.  
In addition to targeting individual cytokines, there may be a role for downstream targets, 
such as that of the JAK/STAT pathway 476. A phase II clinical trial showed that a possible 
improvement in survival of patients with metastatic pancreatic adenocarcinoma when 
JAK1/2 inhibitor Ruxolitinib was used in combination with capecitabine477. Specifically, this 
benefit was seen only in a sub-group of patients with elevated systemic inflammatory 
markers CRP or mGPS. This may suggest a role for scores such as IL10-CEA in patient 














Table A 1. Tumour Characteristics by IL-6, IL-8 and IL-10 
 IL-6 IL-8 IL-10 
 High Low p High Low p High Low P 




3   (27.3) 
15 (50.0) 
10 (31.3)        
  8  (72.7) 
15 (50.0) 
22 (68.8) 
0.23   2 (18.2) 
16 (53.3) 
17 (53.1) 
  9 (81.8) 
14 (46.7)  
15 (46.9) 
0.10   8 (72.7) 
21 (70.0) 
15 (46.9) 
 3  (27.3) 






  4  (50.0) 
24 (36.9) 
 4  (50.0) 
41 (63.1) 
0.48   3 (37.5) 
32 (49.2) 
  5 (62.5) 
33 (50.8) 
0.53   3 (37.5) 
41 (63.1) 
  5 (62.5) 
24 (36.9) 
0.16 




15 (30.6)  
  8 (40.0) 
34 (69.4) 
0.02  9  (45.0) 
24 (49.0)  
11 (55.0) 
25 (51.0) 
0.76 14 (70.0) 
26 (53.1) 
  6 (30.0) 
23 (46.9) 
0.20 




  6 (25.0) 
27 (55.1) 
18 (75.0) 
0.10 26 (53.1)  
  9 (45.0) 
23 (46.9) 
15 (62.5) 





Lympho-vascular Invasion (%) 
Yes 
 No 
  4 (44.4) 
24 (38.1) 
  5 (55.6) 
39 (61.9) 
0.72  5 (55.6) 
30 (47.6) 
  4 (44.4) 
33 (52.4) 
0.66   5 (55.6) 
38 (60.3) 
  4 (44.4) 
25 (39.7) 
0.29 
Perineural Invasion (%) 
Yes 
 No 
 4 (30.8) 
23 (39.7) 
  9 (69.2) 
35 (60.3) 
0.55   5 (38.5) 
29 (50.0) 
  8 (61.5) 
29 (50.0) 
0.45 8   (61.5) 
34 (58.6) 
  5 (38.5) 
24 (41.4) 
0.85 
Microsatellite Instability (%) 
High 
 Low 
  8 (72.7) 
14 (31.1) 
  3 (27.3) 
31 (68.9) 
0.01   8 (72.7) 
20 (44.4) 
  3 (27.3) 
25 (55.6) 
0.09   9 (81.8) 
27 (60.0) 
  2 (18.2) 
18 (40.0) 
0.55 




 IL-6 IL-8 IL-10 CEA 




    22 (78.6)  
13 (28.9) 
  6 (21.4) 
32 (71.1) 
<0.001  18 (64.3) 
 26 (57.8) 
10 (35.7) 
19 (42.2) 










 6  (15.8) 
13 (37.1) 
32 (84.2) 
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Table A 3. Tumour characteristic by CEA, IL8-CEA and IL10-CEA Scores 
 CEA IL8-CEA IL10-CEA 
 High Low p High Low p High Low p 




  4 (36.4) 
14 (46.7) 
19 (59.4)   
  7 (63.6) 
16 (53.3) 
13 (40.6) 
0.36     0 (0.0) 















  5 (62.5) 
32 (49.2) 
  3 (37.5) 
33 (50.8) 
0.48   2 (25.0) 
17 (26.2) 
  6 (75.0) 
48 (73.8) 










  8 (40.0) 
28 (57.1) 
















0.36 12 (24.5) 
  7 (29.2) 
37 (75.5) 
17 (70.8) 





Lympho-vascular Invasion (%) 
Yes 
 No 
  3 (33.3) 
33 (52.4) 
  6 (66.7) 
30 (47.6) 
0.29   2 (22.2) 
17 (27.0) 
  7 (77.8) 
46 (73.0) 





Peri-neural Invasion (%) 
Yes 
 No 
  6 (46.2) 
29 (50.0) 
  7 (53.8) 
29 (50.0) 









Microsatellite Instability (%) 
High 
 Low 
  6 (54.5) 
20 (44.4) 
  5 (45.5) 
25 (55.6) 
0.55   4 (36.4) 
10 (22.2) 
 7 (63.6) 
35 (77.8) 
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